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ABSTRACT 
ENGINEERING SURFACE FUNCTIONALITY OF GOLD NANOPARTICLES FOR 
THERAPEUTIC APPLICATIONS 
 
FEBRUARY 2012 
 
CHAE KYU, B.A., INHA UNIVERSITY 
 
M.A., INHA UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Vincent M. Rotello 
 
 
  Over the past few decades, tremendous efforts have been made to develop 
nanomaterials for biotechnological applications such as therapeutics. Understanding 
and engineering interfaces between biomacromolecules and nanomaterials is a key to 
the creation of successful therapeutic systems. My research has been oriented toward 
developing therapeutic systems using gold nanoparticles (AuNPs) incorporating 
material science, organic synthesis, and biology. For this purpose, mixed monolayer-
protected AuNPs (~2 nm core size) with various functional groups have been employed 
for triggering therapeutic effects. Several strategies have been accomplished using 
anticancer drugs that non-covalently and covalently incorporate onto AuNPs as a drug 
delivery carrier. Alternatively, AuNPs were developed by regulating host-guest 
complexation processes inside the cell, allowing control of the therapeutic effect of the 
AuNP. In addition, by using host-guest chemical events on the AuNPs, exocytosis of 
the AuNPs was controlled, enabling their prolonged retention inside of the cells, 
providing new strategies for improving conventional drug delivery systems. Therefore, 
 vii 
engineering of the AuNP surface can afford new pathways for designing and improving 
therapeutics.   
 viii 
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CHAPTER 1 
 
 
 
 
GOLD NANOPARTICLES IN THERAPEUTICS 
 
 
 1.1 Introduction 
Nanoparticles provide a useful platform, demonstrating unique properties 
gleaning a wide range of therapeutic applications. 1 Monolayer protected metal 
nanoparticles particularly have proven to be the most versatile and widely used 
constituents in biotechnology.2, 3, 4, 5 Nanoparticles represent hybrid systems of nano-scale 
metal cores covered by a self-assembled monolayers of organic ligands. The use of 
nanoparticles in therapeutic applications takes advantage of both the dimensions and the 
physical properties of the inorganic core, as well as the functions of the organic surface 
periphery. 
Nanoparticles exhibit a number of unique physical and chemical properties 
relative to bulk material. The novel properties of nanoparticles arise from a variety of 
attributes, including their enormous surface area. In addition, the versatile and tunable 
properties of nanoparticles are based on their component, size, shape, functionalized 
surface, and chemical surroundings. The unique properties of nanoparticles have attracted 
great interest in the scientific community and have been utilized in various chemical and 
biological applications, including electronic and optical studies, chemical and biological 
sensing, cell labeling and imaging, and cancer therapy.6, 7, 8, 9, 10 Table 1.1 list some well 
known core materials with their corresponding surface ligands and their various 
biological applications. 
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Table 1.1 Characteristics, ligands, and representative applications for various metal and 
semiconductor materials. 
 
Core 
material 
Characteristics  Ligand(s) Applications 
Au Optical 
absorption, 
fluorescence and 
fluorescence 
quenching, 
stability 
Thiol, disulfide, 
phosphine, amine 
Biomolecular 
recognition, delivery, 
sensing, therapeutics 
Ag Surface-enhanced 
fluorescence 
Thiol Sensing 
Pt Catalytic property Thiol, phosphine, 
amine, isocyanide 
Bio-catalyst, sensing 
CdSe Luminescence, 
photo-stability 
Thiol, phosphine, 
pyridine 
Imaging, sensing 
Fe2O3 Magnetic property Diol, dopamine 
derivative, amine 
MR imaging and 
biomolecule 
purification 
SiO2 biocompatibility Alkoxysilane Biocompatible by 
surface coating  
 
Of these metal nanoparticles, the utility of gold nanoparticles (AuNPs) in biology 
has attracted attention due to its biocompatibility,11 controlled fabrication,  and functional 
versatility. 12 , 13 , 14  Stimulated by the pioneering work of Brust et al. in 1994, 15  thiol-
protected AuNPs have evolved to one of the most widely studied particle-ligand systems.16  
The optical, electronic and bioinert properties of the gold core combined with the versatile 
surface functionalization facilitate the applications of these materials in both fundamental 
research and industrial development. 17, 18, 19, 20 These functional nanomaterials have shown 
promising potential in electronics,21 catalysis,22 biosensing,23 and nanomedicine.24  
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Figure 1.1 Schematic illustration of monolayer-protected gold nanoparticles: the 
inorganic gold core protected by an organic monolayer that can feature chemically 
different end group for a myriad of biomedical applications. 
 
The functionalization of gold clusters is achieved through Brust-Schriffrin 
reduction followed by Murray place-exchange reaction 25  with appropriate functional 
ligands.  The incorporation of multiple functionality within the scaffold of a single cluster 
coupled with a scale comparable with biomacromolecules (e.g. proteins and DNA) 
provides multiple applications at the interface of biotechnology and nanomaterials.  For 
instance, some recent studies have shown that proper surface functionalization holds great 
promise in disrupting protein-protein interaction,26 regulating DNA transcription,27 gene 
transfection,28 etc. This thesis work utilized AuNP as a scaffold for designing systems for 
therapeutic applications. Therefore, as a background to this work, synthesis and 
functionalization, properties, and some therapeutic applications of AuNPs will be discussed 
in this chapter. 
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1.2 Synthesis and surface functionalization of gold nanoparticles 
AuNPs can be synthesized either through chemical reduction of gold salts or 
through the physical treatment of bulk gold. The synthesis of AuNPs has been widely 
explored during the past few decades. Concurrently various strategies have been applied 
to control their size, shape, stability, solubility, and surface functionality. AuNPs of 
various sizes can be prepared by using appropriate stabilizing agents during the chemical 
reduction of gold salts. These stabilizing agents provide the necessary barrier to avoid 
particle coalescence. Some common synthetic methods of AuNPs are summarized in 
Table 1.2. 
Table 1.2 Synthetic methods for AuNPs of diverse core size. 
Core size (d)  Synthetic methods Capping agents References 
1-2 nm Reduction of AuCl(PPh3) with diborane or sodium 
borohydride 
Phosphine 29,30,31 
1.5-5 nm Biphasic reduction of HAuCl4 by sodium 
borohydride in the presence of thiol capping agents
Alkanethiol 32,33,34 
5-8 nm Reduction of HAuCl4 by sodium borohydride in 
the presence of TOAB 
Quaternary ammonium salt 
(TOAB) 
35 
8-20 nm Reduction of HAuCl4 by oleyl amine in water 
under heating 
Oleyl amine 36, 37 
10-40 nm Reduction of HAuCl4 with sodium citrate in water citrate 38,39,40 
 
In 1994, the breakthrough in AuNP synthesis was achieved by Brust and 
Schriffin.15 AuNPs soluble in organic solvents were synthesized by using the surfactant 
tetraoctylammonium bromide (TOAB) to transfer hydrogen tetrachloroaurate from 
aqueous phase to toluene phase. In this method, Sodium borohydride was used as 
reducing agent in the presence of alkanethiols. This methodology produces relatively 
monodisperse AuNPs protected by thiol ligands and with diameters ranging from 1.5 to 5 
nm. The nanoparticle size is controllable by varying the reaction conditions such as gold-
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to-thiol ratio, reduction rate, and reaction temperature. Thiol-protected AuNPs possess 
higher stability compared to most other AuNPs due to the synergic effect of strong thiol-
gold interactions and van der Waals attractions between the ligands. These nanoparticles 
can be thoroughly dried and redispersed in solution without any aggregation. In the 
biphasic reduction protocol, slightly larger nanoparticles can be achieved by using 
quaternary ammonium instead of a thiol ligand and show considerable stability in 
solution. These particles serve as excellent precursors for further functionalization of 
nanoparticles. 
Various capping agents (e.g. amino acid,41 oelyl amine, and aliphatic and aromatic 
amines42, 43) have been introduced to reduce gold salts into nanoparticles with different 
core sizes. The size and shape of AuNPs can be further manipulated by physicochemical 
treatments such as light-irradiation and thermolysis. For example, conventional 
ripening44, 45, 46  and digestive ripening47, 48 treatments have been conducted to control the 
nanoparticle size. UV and laser irradiation provides another powerful approach to 
improve quality of the nanoparticle.49, 50   
The capping agents used for synthesizing AuNPs are generally lacking in 
chemical functionality, thus restricting their applications in therapeutics. Place-exchange 
process introduced by Murray is an efficient approach for functionalizing surface of 
AuNPs (Figure 1.2).25 During a place-exchange reaction, the thiol ligands initially 
anchored on the nanoparticle surface are replaced by the external thiol ligands in an 
equilibrium process.51 The loading of functional ligands can be controlled by modulating 
the reaction time and/or the amount of incoming ligand. Mixed monolayer-protected gold 
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clusters can also be obtained by using a mixture of two or more ligands as the incoming 
thiol agents. 
  
Figure 1.2 Synthesis of AuNP and its surface functionalization through place exchange 
reaction. 
 
Labile capping agents, such as citrate, 52 triphenylphosphine, 53  and 
dimethylaminopyridine,54  can be displaced by thiols under mild reaction conditions with 
no residual capping agent.  Citrate-stabilized AuNPs are important precursors for large 
functionalized colloidal ensembles such as those carrying oligonucleotide, protein, or 
antibody functionalities.55, 56 However, chemisorption of thiol ligands onto the citrate-
stabilized nanoparticles leads to their irreversible aggregation.57 Therefore, to prevent 
aggregation, nonionic surfactant such as Tween 20 is usually used during the place-
exchange. The thiol ligands on gold surface possess a certain level of mobility and 
consequently they can undergo repositioning on the surface to optimize interaction with 
analytes.58  
 
1.3 Cellular interaction of gold nanoparticles  
For developing a therapeutic system with AuNPs, an understanding of the 
interaction of AuNPs with cells is important. Cellular uptake and intracellular fate of 
AuNPs depend on surface functionality and size.59 Charge is an important determinant,60 
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Rotello and Vachet have demonstrated that cellular uptake of functionalized AuNPs is 
dependent on both charge and hydrophobicity.61 Stellacci et al. have reported that cell 
membrane penetration of nanoparticle is also dependent on ligand shell morphology,62 
with “striped” (structured ligand shell) nanoparticles apparently capable of directly 
passing through the plasma membrane of the cells without creating pores on cell 
membrane that can cause cytotoxicity (Figure 1.3).  
 
 
Figure 1.3 Schematic diagrams of the ligand shell structure of the nanoparticles and 
representative STM images (scale bars 5 nm). 
 
Furthermore, organelle-specific localization of particles can be easily achieved by 
decorating the surface with a targeting moiety. For example, Feldheim et al. have 
demonstrated nuclear targeting of particles modified with nuclear localization sequence 
(NLS).63 Recently, Brust et al. have used transmission electron microscopy64 to show that 
specific cellular targets such as the nucleus and other organelles can be targeted by 
modifying the particle surface with cell penetrating peptides (CPPs) (e.g. the 
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oligopeptides TAT (AGRKKRRQRRR) and Pntn (GRQIKIWFQNRRMKWKK)) and 
the nuclear localization sequence (NLS: GGFSTSLRARKA) (Figure 1.4).  
 
 
Figure 1.4 Nuclear targeting (A) by PEG-modified nanoparticles functionalized with a 
combination of CPPs (2% TAT and 2% Pntn) and 2% NLS. Nanoparticles are 
highlighted by red circles. The nuclear envelope with nuclear pores (arrows) is clearly 
shown in this image. The nucleus is denoted n, and the cytosol c. Unusual perinuclear 
membranous structures (B and C) that are highly loaded with nanoparticles are typically 
also observed under these conditions. Nuclear targeting is enhanced in comparison with 
experiments in the absence of CPPs (D). Scale bars are 200 nm. 
 
Particle size provides the second key determinant of particle uptake. Chan et al. 
have demonstrated that cellular uptake depends on the size of nanoparticles.65 AuNPs (2-
100 nm) coated with Herceptin were fabricated and tested for ErbB2 receptor-mediated 
internalization in breast cells. They found that most efficient cellular uptake occurred 
with the 20~50 nm particles and programmed cell death (apoptosis) was enhanced by 
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particles the 40–50 nm range. The authors also have investigated the effect of AuNP size 
(10-100 nm) on passive targeting of tumors in vivo.66 The larger nanoparticles remained 
near the vasculature, whereas smaller nanoparticles rapidly diffused from blood vessels to 
tumor matrix (Figure 1.5). 
 
 
Figure 1.5 Particle size-dependent permeation of the tumor interstitial space. (A-C) 
Histological samples were obtained for 20, 60, and 100 nm particle sizes at 8 h 
postinjection (HPI). (D) ImageJ software was used to generate contrast-enhanced images 
for densitometry analysis. (E) Densitometry signal was quantified at 10m distances 
away from blood vessel centers 8 HPI and was normalized to the signal at 0-10 μm66. 
 
1.4 Gold nanoparticles in drug delivery  
Considerable effort has been focused on the creation of drug delivery systems 
(DDS) for improving efficacy of cancer chemotherapy, with the goals of enhancing 
therapeutic selectivity and efficacy. 67  One area where DDSs have proved highly 
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beneficial is in targeted delivery, where marked improvements in chemotherapy have 
been achieved through passive and/or active targeting approaches with nanocarriers 
including liposomes, 68  polymer micelles and vesicles, 69  dendrimers, 70  and metal 
nanoparticles.71 
AuNPs have recently emerged as highly promising DDSs.72 AuNPs have multiple 
aspects that make them well-suited for use in delivery applications over other 
nanocarriers. First, AuNPs of many different sizes (1-150 nm) can be fabricated in a 
controlled fashion with control over size dispersity,73 while polymer based carriers have 
the issue caused by the intrinsic heterogeneous structure of polymers due to a high 
polydispersity index indices. Furthermore, due to their high surface area to volume ratio, 
a high density of ligands can be archived on the surface of AuNPs for targeting or drug 
loading purpose. For example, 2-nm core sized AuNP has around 100 lignads on 
particles.34 Second, functional diversity can be readily achieved by creation of 
multifunctional monolayers using techniques such as the ligand place-exchange reaction, 
allowing multiple functional moieties such as anticancer drugs and targeting agents to be 
placed onto the particle surface. In terms of the mitifunctionalization, dendrimers are a 
promising nanocarrier with a well defined structure. However, many repetitive steps for 
synthesis and expensive production are major challenges. Lastly, the gold core is 
essentially inert, non-toxic, and biocompatible.74 
The facile functionalization of AuNP surface has enabled their use in a variety of 
delivery strategies. In one approach, prodrugs can be covalently conjugated to AuNPs via 
cleavable linkers. Alternatively, hydrophobic drugs can be non-covalently loaded onto 
AuNPs, allowing conjugation without structural modification of the drug payload. Once 
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loaded, AuNP payloads can be released by either internal (e.g. glutathione)12 or external 
(e.g. light) 75  stimuli. The versatility of the AuNP monolayer is central to release 
mechanisms, providing tunability for endogenous release mechanisms and a functional 
platform for external release strategies. 
 
1.4.1 Drug attachment and release strategies using gold nanoparticles 
Both the transport and release of drugs play critical roles in providing effective 
delivery systems. In general drugs can be loaded onto nanocarriers by either covalent 
conjugation or non-covalent interactions.76 The non-covalent approach employs active 
drugs while the covalent attachment generally requires intercellular processing of a 
prodrug.77 The ease of controlling the functionality and structure of AuNP monolayers 
makes them excellent platforms for DDS creation. 
DDS systems based on glutathione (GSH)-mediated payload release exploit the 
dramatically higher intracellular GSH concentration (1–10 mM)78 relative to extracellular 
thiol levels (GSH 2 M, cysteine 8 M). 79 The high levels of intracellular GSH can be 
used to release prodrugs (payloads) on AuNPs through either place-exchange reactions at 
the core or via disulfide exchange. Importantly, the monolayer of nanoparticles can 
provide steric shielding against exchange with surface cysteines of proteins in the 
bloodstream,80 enabling their potential use in vivo. 
In early studies, Rotello et al. developed a nanoparticle-based delivery system 
featuring glutathione release. The particles (core diameter: ~ 2 nm) featured a mixed 
monolayer composed of cationic ligands (TTMA) and fluorogenic ligands (HSBDP) 
(Figure 1.6). The cationic surface of the nanoparticles facilitated the penetration through 
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cell membrane, and the payload release was triggered by intracellular glutathione (GSH). 
In this delivery system, the BODIPY moiety of the HSDBP ligand was non-fluorescent 
when attached to the particle due to fluorescence quenching by the Au core.81  The 
fluorescence was recovered upon GSH treatment in cuvette, or with intracellular thiols in 
human liver cells (Hep G2). GSH-controlled release of the dye was verified by treating 
mouse embryonic fibroblast cells (MEF, having >50% lower intracellular GSH levels 
than HepG2) with varying concentration of glutathione monoester (GSH-OEt), 
transiently increasing glutathione level inside the cells. In these studies, a dose-dependent 
increase in fluorescence was observed with increasing GSH-OEt concentration. In a 
similar fashion, AuNP-mediated DNA transfection efficiency was regulated by 
controlling the intracellular glutathione level.82  
The ligand-displacement rate by intracellular thiols (e.g. DHLA and GSH) 
depends strongly on the monolayer structure and surface charge,83 allowing controlled 
release of payload. As an example, Kotov et al. have demonstrated that AuNPs bearing 6-
mercaptopurine-9-　-D-ribofuranoside significantly enhanced the anti-proliferative effect 
against K-562 leukemia cells compared to the same drug in free form. 84  This 
improvement was attributed to enhanced intracellular transport followed by the 
subsequent GSH-mediated release in cytoplasm and lysosomes.  
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Figure 1.6 (A) Schematic illustration of GSH-mediated surface monolayer exchange 
reaction/payload release. (B) Fluorescence images of MEF cells displaying GSH-
controlled release of the fluorophore after incubation with 0, 5, and 20 mM GSH-OEt.  
In a strategy that combines glutathione-mediated release with non-covalent 
loading of drugs (vide infra), Kim et al. reported cyclodextrin-functionalized AuNPs as 
carriers of anti-cancer drugs.85 The AuNPs used the cyclodextrin moieties to encapsulate 
drugs, anti-epidermal growth factor receptor (anti-EGFR) antibody as a targeting moiety, 
and poly(ethyleneglycol) (PEG) as an anti-fouling shell (Figure 1.7). The anticancer drug 
　-Lapachone, was efficiently encapsulated into the hydrophobic cavity of cyclodextrin 
onto AuNPs and then released by intracellular GSH. The introduction of an anti-EGFR 
antibody onto the AuNPs was shown to both enhance the uptake of AuNPs and increase 
the degree of apoptosis.  
 14 
 
Figure 1.7 Schematic illustration of the functionalization of AuNP with -lapachone, 
using: i) SH-CD and mPEG-SH for AuNP-1 (RhoCD and mPEG-SH for RhoCD-AuNP-
1); ii) SH-CD, mPEG-SH, and NHS-PEG-SH for AuNP-1.5 (RhoCD, mPEG-SH, NHS-
PEG-SH for RhoCD-AuNP-1.5) and iii) anti-EGFR.  
 
1.4.2 Encapsulation of therapeutics in monolayer of gold nanoparticles 
Non-covalent incorporation of drugs into AuNP monolayers provides an 
alternative delivery strategy that allows direct use of unmodified drugs, thus avoiding 
prodrug processing issues. Drug encapsulation with AuNPs relies on the use of ligands 
that generate a hydrophobic interior to the monolayer. Structurally, the radial nature of 
the monolayer results in a decrease in ligand density as one goes further from the core of 
small AuNP cores (< ~6 nm).86 Consequently “hydrophobic pockets” are created inside 
the monolayer of the AuNP into which hydrophobic materials can be partitioned. 
Pasquato et al. demonstrated the encapsulation of radical probes in AuNP monolayers, 
using EPR spectroscopy to monitor the partition of the lipophilic probe between 
 15 
monolayer of AuNP and bulk water.87 As expected, smaller particles featuring more 
strongly radial monolayers favor guest encapsulation (Figure 1.8). 
 
 
Figure 1.8 (A) Schematic representation of AuNP and the nitroxide probe inclusion. (B) 
Plot of the ratio between the concentration of 2 partitioned in the monolayer and that of 
the free species ( 16 nm;  3.4 nm;  5.3 nm) as a function of [HS-C8-TEG] bound 
to the gold. 
 
The concept of monolayer encapsulation has recently been applied to drug 
delivery. Rotello et al. have developed a biocompatible AuNP carrier that employs 
hydrophobic pockets to encapsulate drugs and deliver them into cancer cells. 88  The 
particles (~ 2.5 nm core) featured a hydrophobic alkanethiol interior and a hydrophilic 
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shell composed of a tetra(ethylene glycol) (TEG) unit terminated with a zwitterionic 
headgroup designed to minimize nonspecific binding with biomacromolecules 89  and 
other cell surface functionality (Figure 1.9). Hydrophobic payloads were kinetically 
entrapped in the monolayer, with the resulting host-guest materials stable in buffer and 
serum. The entrapped payloads were released into cells by membrane-mediated diffusion, 
as demonstrated by both fluorescence microscopy (using a fluorophore payload) and 
through drug efficacy with therapeutic guests. No particle uptake was observed with 
these systems using ICP-MS, making these systems excellent candidates for passive 
targeting using the enhanced permeability and retention (EPR) effect.90 
 
 
Figure 1.9 (A) Structure of particles and guest compounds: Bodipy, TAF, and LAP, the 
number of encapsulated guests per particle (B) Cytotoxicity of AuNPZwit complexes 
measured by Alamar blue assay after 24 h incubation with MCF-7 cells. IC50 of AuNP 
(NP), equivalent drugs (Drug), and free drugs are shown in table. 
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Photodynamic therapy (PDT) is a promising strategy that uses reactive oxygen 
species (ROS) to induce apoptosis or necrosis. Burda et al. reported the use of PEGylated 
AuNP-Pc4 (Si-phthalocyanine) conjugates as efficient platforms for PDT (Figure 1.10 
(a)).91 The phthalocyanine photosensitizing agent was encapsulated by the PEG ligands 
through van der Waals interaction, with the PEG ligand inhibiting colloid aggregation 
and providing significant resistance to non-specific binding with biomacromolecules. The 
release of Pc4 from AuNP in vitro in a two-phase solution system and in vivo in cancer-
bearing mice (Figure 1.10 (b)) indicated that the delivery process was highly efficient, 
with Pc4 preferentially accumulated in tumor sites. With the Au NP-Pc 4 conjugates, the 
drug delivery time required for PDT was reduced from 2 days using the free drug to 2 h, 
using the conjugate (Figure 1.10).  
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Figure 1.10 (A) Sturcture of the water-soluble AuNPs as a PDT drug delivery agent, Pc 4 
structure (B) Fluorescence images of a tumor-bearing mouse after being injected with Au 
NP-Pc 4 conjugates in normal saline (0.9% NaCl, pH 7.2), (a) 1 min, (b) 30 min, and (c) 
120 min after intravenous tail injection. Any bright signal is due to Pc 4 fluorescence. For 
comparison, a mouse that got only a Pc 4 formulation without the AuNP vector injected 
is shown in panel (d). No circulation of the drug in the body or into the tumor was 
detectable 2 h after injection without the AuNP as a drug vector. 
 
1.4.3 Light-regulated release of payload  
The ability to regulate drug release is an important property for drug delivery 
systems. While endogenous approaches such as GSH-mediated release provide very 
useful strategies for delivery, externally controlled release provides a complementary tool 
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for site- and time-specific control of payload release.92 Recently, caged drugs have been 
developed where the activity of the drug was suppressed by attaching it to a blocking 
element through a photoremovable protecting group.93 Rotello et al. have applied this 
strategy to AuNP delivery vehicles, utilizing a photo-cleavable o-nitrobenzyl ester moiety 
that dissociates upon light irradiation to alter the surface potential from positive to 
negative, thereby releasing adsorbed DNA. In more recent studies, the authors 
demonstrated light-controlled release of anticancer drug (5-fluorouracil) from 
nanoparticles (Figure 1.11).94 The AuNPs (Au_PCFU, Au core: ~2 nm) featured a mixed 
monolayer of zwitterionic and photocleavable ligands. The zwitterionic ligand provided 
solubility and prevented cellular uptake. The photocleavable ligand linked the 
fluorouracil to the particle through an orthonitrobenzyl group that could be effectively 
cleaved using near-UV irradiation (365 nm). An IC50 value of 0.7 M observed upon 
irradiation for Au_PCFU on a per particle basis, whereas no significant cell death was 
observed in cells treated with only light or only Au_PCFU. 
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Figure 1.11 (A) Photochemical reaction (365 nm) of Au_PCFU and delivery of payload 
to cell. (B) Cytotoxicity of different concentrations of Au_PCFU under uncaging  
conditions. The IC50 value was 0.7 M per particle, 11.9 M per drug. 
In related research, Nakanishi et al. have reported a photoresponsive nanocarrier 
of amines, including cell signaling agents. (Figure 1.12).95  In this approach a carbamate 
linkage could be dissociated via the photocleavage reaction of the 2-nitrobenzyl group 
upon near-UV irradiation. The caging process was very effective: histamine had no 
biological activity while it was attached to AuNPs but became active when it was 
released from the particles upon photo-irradiation.  
 
1.4.4 Other attachment/release strategies  
A variety of additional delivery strategies have been developed using AuNP 
platforms. Schoenfisch et al. have demonstrated that nitric oxide (NO) can be efficiently 
released at acidic pH from gold nanoparticles, 96  providing a potential means of 
controlling multiple cellular processes including angiogenesis, vasodilation, and the 
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immune response.97 Hwu et al. have used a phosphate linker to conjugate paclitaxel to 
AuNP and Fe3O4 particles. 98  The drug could be released from the particles using 
phosphodiesterase.  
 
 
 
Figure 1.12 Capture and release of amines on GNPs having a photocleavable 
succinimidyl ester.  
 
1.5 Dissertation overview  
Engineering the interfaces between biomolecules and nanomaterials is important 
for the creation of systems with potential applications in therapeutics. My research has 
been oriented toward biotechnological applications in cancer therapy via engineering the 
interface between biomacromolecules and nanomaterials. For the purpose, I have 
employed a synergistic approach, combining materials, surface science, organic 
synthesis, and biology to develop surface functionalized AuNPs with a tailored 
monolayer. In the following chapters, details of designing functionalized AuNPs and 
their use in therapeutic applications are described. 
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Figure 1.13 Dissertation overview. Schematic illustration of therapeutic applications of 
AuNPs described in this thesis. 
 
In Chapter 2, AuNPs with non-covalent loading of drugs on the monolayer will be 
discussed. Non-covalent incorporation of drugs into AuNP monolayers provides an 
alternative delivery strategy that allows direct use of unmodified drugs, thus avoiding 
prodrug processing issues. Hydrophobic payloads were kinetically entrapped in the 
monolayer with the resulting host–guest materials stable in buffer and serum. Upon 
incubation with cancer cells, the entrapped payloads were efficiently released into cells 
by membrane-mediated diffusion without cellular uptake of the particles, showing 
therapeutic efficiency. This system is an excellent candidate for passive targeting using 
the enhanced permeability and retention effect. 
Chapter 3 will discuss about pH-labile prodrugs incorporated AuNPs with 
positive or negative surface charges to study diffusion of the payloads and their carrier in 
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cylindroids tumor model. Anticancer drugs are attached on the AuNP surface through 
acid-cleavable linkers, allowing pH induced drug release. Positively charged 
nanoparticles improved delivery of payloads to the majority of cells in tumours, whereas 
negatively charged particles would perform better when delivering drugs deep into 
tissues. The ability to tune surface charge to control tissue penetration and drug release 
makes gold nanoparticles a flexible and powerful drug delivery vehicle. 
Chapter 4 will illustrate the recognition mediated activation of therapeutic AuNPs 
through regulation of synthetic host-guest complexation process inside the living cell. We 
will describe a supramolecular synthetic host-guest system featuring diaminohexane 
terminated AuNPs (AuNP-NH2) and cucurbit[7]uril (CB[7]). In this system, threading of 
CB[7] on the particle surface reduces the cytotoxicity of the AuNP-NH2 by sheathing the 
lethal diaminohexane ligand. Intracellular triggering of the therapeutic effect of AuNP-
NH2 was achieved via the administration of 1-adamantylamine (ADA). ADA binds to 
CB[7] with higher affinity than the diaminohexane ligand and thus removes CB[7] from 
the nanoparticle surface. This intracellular disassembly of AuNP-NH2 and CB[7] 
complex activates the in situ cytotoxicity of AuNP-NH2 and hence induced cell death. 
This result presents a new strategy for triggering therapeutic systems through the use of 
competitive interactions of orthogonally presented guest molecules. 
In Chapter 5, regulating exocytosis of AuNPs by using host-guest chemistry will 
be discussed. AuNPs featuring quaternary amine head groups were internalized into the 
cells by endocytosis. Subsequent in situ treatment of a complementary cucurbit[7]uril 
(CB[7]) to the amine head groups induced the particles-CB[7] complexation inside of the 
cells, rendering the particles assembled each other. The larger induced particle assemblies 
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remained sequestered in the endosomes, inhibiting exocytosis of the particles without any 
observed cytotoxicity. This approach would provide a potential strategy for prolonged 
retention of drug carriers within endosome, enabling sustained release of the loaded 
therapeutics in the carriers.  
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CHAPTER 2 
 
 
 
 
ENTRAPMENT OF HYDROPHOBIC DRUGS IN GOLD NANOPARTICLE 
MONOLAYERS WITH EFFICIENT RELEASE INTO CANCER CELLS 
 
 
 
2.1 Introduction 
 
Drug delivery systems (DDSs) provide an important tool for increasing efficacy 
of pharmaceuticals through improved pharmacokinetics and biodistribution. 1  A wide 
variety of nanoscale materials such as liposomes, polymeric micelles, and dendrimers, 
have been employed as drug carriers.2 Both covalent and non-covalent approaches can be 
applied to the conjugation of drugs into these DDSs.3,4 Non-covalent approaches have the 
capability of employing active drugs, whereas covalent attachment generally requires 
chemical modification which can cause reduced efficiency of drug release or incomplete 
intracellular processing of a prodrug.5  
Recently, gold nanoparticle (AuNP) based drug/gene delivery systems have 
attracted attention due to their functional versatility,6 biocompatibility,7 and low toxicity,8 
Recent studies have demonstrated controlled release of payload by intracellular thiols.9, 10, 
11, 12, 13 However, controlled dissociation of drugs in active form from covalent AuNP-
drug conjugates remains a challenge for clinical applications.2 
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2.1.1 Non-covalent loading of the drugs on gold nanoparticles 
Non-covalent incorporation of drugs into AuNP monolayers provides an 
alternative delivery strategy with the potential for avoiding drug release and prodrug 
processing issues. The structure of commonly used water-soluble AuNPs is similar to that 
of unimolecular micelles such as dendrimers, featuring a hydrophobic interior and a 
hydrophilic exterior (Figure 2.1). 14  The alkanethiol monolayer of the nanoparticle 
coupled with the radial nature of the ligands15 creates “hydrophobic pockets” inside 
monolayer of AuNP where organic solutes can be partitioned, as demonstrated by 
Lucarini and Pasquato.16 We report here the use of these pockets to encapsulate drugs and 
deliver them with high efficiency to cells. This work has been reported as a 
communication in the Journal of the American Chemical Society.17  
The biocompatible AuNPs used in this study feature two functional domains: a 
hydrophobic alkanethiol interior and a hydrophilic shell composed of a tetraethylene 
glycol (TEG) unit terminated with a zwitterionic headgroup. Particles with this general 
structure have been shown to minimize non-specific binding with biomacromolecules.18, 
19 
 
 
Figure 2.1 Delivery of payload to cell through monolayer-membrane interactions. 
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2.2 Results and discussion  
2.2.1 Loading of drugs/dyes in the monolayer of gold nanoparticles  
We chose three different hydrophobic guest compounds: 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene (Bodipy) as a fluorescent probe,20 and the highly hydrophobic 
therapeutics tamoxifen (TAF) and -lapachone (LAP) as drugs (Figure 1). The 
nanoparticle-payload conjugates (AuNPZwit-Bodipy, TAF, and LAP) were prepared by 
the solvent displacement method.21 First, AuNPZwit (Au core: 2.5 ± 0.4 nm) and guest 
were dissolved in an acetone/water mixture and the solvent slowly evaporated. The bulk 
of the excess guest precipitated out and was removed by filtration; the particles were 
further purified by multiple filtrations through a molecular weight cutoff filter until no 
free guest was observed, followed by dialysis against buffer. The number of entrapped 
guest molecules per particle was determined from 1H NMR spectrum and NaCN-induced 
decomposition experiments and varied depending on size, hydrophobicity (logP), and 
molecular structure of hydrophobic molecules (Figure 2.2). The particle/guest complexes 
are stable in buffer for >1 month and to extended dialysis, a level of kinetic entrapment 
greater than that observed with dendrimers.  
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Figure 2.2 Structure of particles and guest compounds: Bodipy, TAF, and LAP, and the 
number of encapsulated guests per particle. 
 
 
2.2.2 Stability of gold nanoparticles-payloads   
The ability of the delivery systems to release their payload was first explored 
using AuNPZwit-Bodipy in a two-phase dichloromethane (DCM)-water system. In this 
system the dye is quenched by the AuNP, and photoluminescence (PL) only observed 
upon dye release. In these studies a rapid increase in PL intensity is observed along with 
transfer of Bodipy into the DCM layer (Figure 2.3 (a)). Significantly, since no release is 
observed in monophasic aqueous conditions and no particle was observed in the DCM 
layer, payload release presumably occurs via a particle-interface process. 
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Figure 2.3 a) Release of Bodipy from AuNPZwit-Bodipy in DCM-aqueous solution two-
phase systems (ex= 499 nm, em= 517 nm) b) PL intensity AuNPZwit-Bodipy in cell 
culture medium and 100 % serum, indicating little or no release relative to AuNPZwit-
Bodipy in PBS after NaCN-induced release of guest molecules (ex= 499 nm, em= 510 
nm). 
 
2.2.3 Cellular uptake of the gold nanoparticles and their payloads  
Payload delivery to cells using AuNPZwit-Bodipy was determined by confocal 
laser scanning microscopy (CLSM) using human breast cancer (MCF-7) cells. Efficient 
delivery of the dye to the cytosol is observed after 2 h incubation with AuNPZwit-Bodipy 
(Figure 2.4 (a)-(c)). Cellular uptake of nanoparticle was studied using transmission 
electron microscopy (TEM), and inductively coupled plasma mass spectrometry (ICP-
MS), using the analogous cationic particle/dye conjugate AuNPTTMA-Bodipy as a 
positive control. Little or no cellular uptake of AuNPZwit was observed by either TEM 
(Figure 2.4 (d) and (e)) or ICP-MS (Figure 2.4 (f)) for AuNPZwit-Bodipy, whereas 
substantial particle uptake was observed with AuNPTTMA-Bodipy Since no free dye 
was observed during the 24 h incubation of AuNPZwit-Bodipy in medium and serum 
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solution at 37 ºC (Figure 2.3 (b)), Bodipy delivery presumably occurs via a monolayer-
membrane transfer process, consistent with our in vitro studies. 22 
 
 
 
 
 
Figure 2.4 CLSM images of MCF-7 cell treated with AuNPZwit-Bodipy for 2h: (a) 
green channel (b) bright field, and (c) overlap. TEM images of fixed cell treated with (d) 
AuNPZwit-Bodipy and (e) AuNPTTMA as a positive control, Endosomally trapped 
AuNPs are marked by arrow. (f) ICP-MS measurement. (200,000 cells/well), NPZwit: 
AuNPZwit-Bodipy and NPTTMA: AuNPTTMA-Bodipy) indicating little cellular uptake 
of nanoparticle with AuNPZwit-Bodipy. 
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2.2.4 Delivery of the anticancer drugs into the cancer cells   
Demonstration of drug delivery to MCF-7 cells was determined through 
cytotoxicity studies of free and encapsulated drugs using an Alamar blue assay (Figure 
2.5). Notably, AuNPZwit itself was non-toxic at 30 M. In contrast, IC50 values of 4 µM 
and 4.6 µM were observed using AuNPZwit-LAP and AuNPZwit-TAF, respectively. The 
delivery process was quite efficient, with the per drug molecule IC50 of AuNPZwit-TAF 
(46 µM) only three-fold higher than that of TAF (16 M), and that of AuNPZwit-LAP 
(6.0 µM) essentially identical to that of LAP (5.2 M).  
 
 
Figure 2.5  Cytotoxicity of AuNPZwit complexes measured by Alamar blue assay after 
24h incubation with MCF-7 cells. IC50 of AuNP (NP), equivalent drugs (Drug), and free 
drugs are shown in table. 
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2.3 Summary and future outlook  
In conclusion, we have demonstrated that hydrophobic dyes/drugs can be stably 
entrapped in the hydrophobic pocket of AuNPs and released into cell by membrane-
mediated diffusion without uptake of the carrier nanoparticle. Importantly, the small size 
of these nanocarriers coupled with their biocompatible surface functionality should 
provide long circulation lifetimes and preferential accumulation in tumor tissues by the 
enhanced permeability and retention (EPR) effect.23  Additionally, the non-interacting 
nature of their monolayer should make these systems highly amenable to targeting 
strategies. 
 
2.4 Synthesis of materials and experimental methods  
General 
  Dichloromethane (DCM) used after distillation under CaCl2 and other chemicals from 
Aldrich were used as received. Dimethylamine, 1,3-Propanesulfone, trifluroacetic acid 
(TFA), triisopropylsilane (TIPS), and tamoxifen (TAF) were purchased from Aldrich. 
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (Bodipy), β-lapachone (LAP), and 
AuNPTTMA were prepared by the literature procedures.24, 25, 26 Theramanox® coverslips, 
uranyl acetate, osmium tetroxide, glutaraldehyde, lead citrate, epoxy embedding kit (Low 
Viscosity, as reported by Dr. Spurr) and 300 mesh copper grids with carbon film were 
purchased from Electron Microscopy Sciences.  
 1H and 13C NMR spectra were recorded on a Bruker AVANCE 400 at 400 and 100 MHz, 
respectively. ESI-MS spectra were obtained using JEOL MStation JMS700. UV-vis 
spectra were recorded on Hewlett-Packard 8452A spectrophotometer. Photoluminescence 
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spectrum was measured using Photon Technology International fluorescence 
spectrometer. Dynamic light scattering (DLS) was measured by Zetasizer Nano ZS. 
Fixed cell sections for TEM were cut by using Reichert Ultracut E Ultramicrotome and 
imaged using JEOL 100S electron microscopy. Cell viability using Alarmar blue assay 
was assessed by SpectraMax M5 microplate spectrophotometer and plotted by Origin 8. 
Fluorescence images was obtained using Zeiss LSM510 meta confocal microscope. 
 
2.4.1 Synthesis of ligand and fabrication of nanoparticle  
 
 
Figure 2.6 Synthesis of HS-C11-TEG-Zwit. (a) Dimethylamine, DCM, RT, overnight (b) 
1,3-Propanesulfone, acetone, RT, overnight, (c) TFA, TIPS, RT, 4h 
 
Compound 2 
Compound 1 (1 g, 1.4 mmol) was added to a solution of dimethylamine (0.6 g, 14 mmol 
in dichloromethane (20 mL) and the reaction mixture was stirred at room temperature for 
overnight. The reaction mixture was poured into a mixture of dichloromethane and 
distilled water. Organic layer was separated and concentrated at reduced pressure. The 
crud product was purified by column chromatography over silica gel using hexane/ethyl 
acetate (1:4, v/v) as an eluent. Solvent was removed in vacuo to afford compound 2 as 
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colorless oil (Yield 0.6 g, 65 %). 1H NMR (400 MHz, CDCl3)  7.41 (m, 6H, Ph-), 7.27 
(m, 6H, Ph-), 7.20 (m, 3H, Ph-), 3.65-3.56 (m, 14H, -CH2-TEG-), 3.44 (t, J = 6.8 Hz, 2H 
-OCH2-CH2-N(CH3)2), 2.53 (t, J = 5.8 Hz, 2H, -OCH2-CH2-N(CH3)2), 2.84 (s, 6H, -
N(CH3)2), 2.14 (t, J = 7.3 Hz, 2H, -S-CH2-), 1.40 (m, 18H, -S-CH2-(CH2)9-); 13C NMR 
(100.64 MHz, CDCl3)  26.10, 28.60, 29.02, 29.19, 29.41, 29.48, 29.56, 29.65, 32.04, 
45.81, 58.77, 66.36, 69.23, 70.07, 70.40, 70.61, 71.55, 126.49, 127.79, 129.62, 145.10. 
Compound 3 
A anhydrous acetone solution (20 mL) of compound 2 (0.5 g, 0.77 mmol) and 1,3-
propanesultone (0.14 g, 1.15 mmol) in anhydrous acetone was stirred at room 
temperature for overnight. The reaction mixture was filtered, and the resulting solid was 
washed with ethyl acetate/hexane (1:4, v/v) and dried in vacuum to afford compound 3 as 
a white solid (Yield 0.5 g, 84 %). 1H NMR (400 MHz, CDCl3)  7.41 (m, 6H, Ph-), 7.27 
(m, 6H, Ph-), 7.20 (m, 3H, Ph-), 3.94 (m, 2H, -OCH2-CH2-N(CH3)2-), 3.78 (m, 2H, -
OCH2-CH2-N(CH3)2-), 3.71-3.56 (m, 14H, -CH2-TEG- and -CH2-CH2-CH2-sulfonate), 
3.42 (t, J = 6.8 Hz, 2H, -OCH2-CH2-N(CH3)2-), 3.23 (s, 6H, -N(CH3)2-), 2.88 (t, J = 6.7 
Hz, 2H, -CH2-CH2-CH2-sulfonate), 2.26 (m, 2H, -CH2-CH2-CH2-sulfonate), 2.12 (t, J = 
7.3 Hz, 2H, -S-CH2-), 1.40 (m, 18H, -S-CH2-(CH2)9-); MS (ESI-MS) calcd for 
C43H66NO7S2 773.12, found 794.6 [M+Na]+ 
 
HS-C11-TEG-Zwit 
A dichloromethane solution of compound 3 (0.6 g, 0.77 mmol), trifluoroacetic acid (1.78 
g, 16 mmol), and triisopropylsilane (0.18 g, 1.1mmol) was stirred at room temperature for 
6 h under argon. After removal of the solvent at reduced pressure, the residue was 
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purified by washing with diethyl ether (20 ml x 5). After drying residue under high 
vacuum, white solid of product was obtained. (Yield 0.36 g,87 %) 1H NMR (400 MHz, 
CDCl3) 3.91 (m, 2H, -OCH2-CH2-N(CH3)2-), 3.79-3.52 (m, 16H, OCH2-CH2-N(CH3)2-, -
CH2-TEG-, and -CH2-CH2-CH2-sulfonate), 3.42 (t, J = 6.8 Hz, 2H, -OCH2-CH2-N(CH3)2-
), 3.41 (t, J = 6.8 Hz, 2H, -OCH2-CH2-N(CH3)2-), 3.04 (s, 6H, -N(CH3)2-), 2.90 (brs, 2H, 
-CH2-CH2-CH2-sulfonate), 2.49 (q, J=7.2 Hz, 2H, HS-CH2-), 2.26 (brs, 2H, -CH2-CH2-
CH2-sulfonate), 1.40 (m, 18H, -S-CH2-(CH2)9-); MS (ESI-MS) calcd for C24H52NO7S2 
530.32, found 552.4 [M+Na]+. 
 
Preparation of AuNPZwit 
Gold nanoparticles, C5 NP were prepared by following the Brust-Schiffrin two-phase 
method using 1-pentanethiol as capping ligands. To fabricate AuNPZwit via ligand place 
exchange reaction, 30 mg of C5 NP were mixed with 100 mg of HS-C11-TEG-Zwit in 
dichloromethane (10 mL). The solution was stirred at room temperature for 24 hours. 
Solvent was removed by rotary evaporator and the nanoparticles were washed with 
diethyl ether (20 mL x 5). The nanoparticles were further purified by dialysis in MiliQ 
water using SnakeSkin pleated dialysis tubing (10,000 MWCO) for 1days. 1H NMR 
spectrum is shown in Figure 2.8 (a).  
    
Figure 2.7 Synthetic pathway of AuNPZwit. 
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2.4.2 Experimental methods  
Preparation and characterization of AuNPZwit complexes (AuNPZwit-dye/drug 
conjugates)  
  In order to prepare AuNPZwit complexes, solvent displacement method was carried out 
using water and acetone. An acetone solution of each guest compound (10 mg) and 
aqueous solution of AuNPZwit (80 M) were well mixed. Acetone was then removed by 
rotary evaporator or slow evaporation at room temperature. During the evaporation of 
acetone, some guest compounds were entrapped in interior of AuNPZwit due to 
hydrophobic interaction and the rest of guest compounds were precipitated out. The 
mixture was then filtrated using filter (0.2 m pore) to remove the precipitate. Any 
residue of free guest compounds in the aqueous solution may affect to result of 
cytotoxicity and fluorescence related experiments. For further purification, the 
AuNPZwit complexes solution was washed with distilled water and centrifuged with 
Amicon Ultra-4 tube (10,000 MWCO) several times (2 mL x ~5 times) until no 
absorbance of guest molecules in filtrate was detected by spectrophotometer. 
AuNPTTMA-Bodipy was also prepared by the same procedure. 
  AuNPZwit complexes conjugates were characterized by nuclear magnetic resonance 
(NMR). 1H NMR spectrum of AuNPZwit complexes are shown in Figure 2.8 (b)-(d). A 
broaden of 1H NMR peak of the guest compounds indicates that guest compounds were 
entrapped in hydrophobic pocket of the AuNPZwit. It is also noted that the H1 NMR peak 
of guest compounds (TAF and Bodipy) in D2O was not present until AuNPZwit complex 
was formed. The stoichiometry of the AuNPZwit complexes was calculated by measuring 
integral of AuNPZwit and guest compounds. From TGA and TEM analysis, it is 
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estimated that 100 ligands are placed on each AuNPZwit.27 Around 10~11 TAFs were 
entrapped in AuNPZwit. The number of entrapped guest compounds for AuNPZwit-LAP 
and AuNPZwit-Bodipy were calculated from the NaCN-induced decomposition 
experiment due to weak 1H NMR signal of guest compound.  
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Figure 2.8 1H NMR spectrum of AuNPZwit and AuNPZwit complexes (a) AuNPZwit 
(b) AuNPZwit-TAF, (c) AuNPZwti-LAP, (d) AuNPZwit-Bodipy.  
 
 
NaCN-induced decomposition of AuNPZwit complexes 
  To 1 ml of a solution of the desired AuNPZwit complexes in THF (final concentration 
of 0.5 ~ 4 μM) was added 1 mL of an aqueous NaCN solution (final concentration 0.1 M) 
followed by briefly agitating the mixture. After 2 h, plasmon absorption band of the 
AuNP at 520 nm completely decayed while absorbance of guest compounds remained. 
Concentration of guest compounds was then calculated based on the Beer-Lambert law 
(λmax = 496 nm for Bodipy, λmax = 290 nm for LAP, and λmax = 280 nm for TAF). By 
comparing with the concentration of AuNPZwit before etching, the number of guest 
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compounds entrapped in AuNPZwit was estimated. A molar extinction coefficient of free 
guest compounds in THF/H2O (1:1) was obtained for this estimation (Bodipy ε = 7.07 x 
103 at 496 nm, LAP ε = 1.2 x 104 at 290 nm, and TAF ε = 1.1 x 104 at 280 nm).  
 
 
 
 
 
Figure 2.9 UV-vis spectrum of AuNPZwit complexes before and after NaCN-induced 
decomposition experiment. (a) AuNPZwit-TAF, (b) AuNPZwit-LAP, and (c) AuNPZwit-
Bodipy. 
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Stability test of AuNPZwit complexes in PBS 
 1 mL of AuNPZwit complexes (5 μM) in PBS was centrifuged with Amicon Ultra-4 
tube (10,000 MWCO) at 8,000 rpm for 30 min. Stability of AuNPZwit complexes was 
examined by measuring the absorbance of the filtrate. Any absorbance of guest 
compound in filtrate was not observed at least for one month.  
 
Partition Coefficient logP 
  Partition coefficient, logP was obtained according to our previous study.28 The logP for 
the hydrophobic compounds as followings: LAP: 2.68, TAF: 3.64, and Bodipy: 4.0. It 
indicates that LAP is less hydrophobic than TAF and Bodipy, which might cause the 
lower number of encapsulated guests in AuNPZwit. 
 
Cell culture 
  MCF-7 cells were grown in a cell culture flask in low glucose Dulbecco's Modified 
Eagle Medium supplemented with 10% fetal bovine serum (FBS) and 1 % of antibiotics 
at 37 °C in a humidified atmosphere of 5 % CO2.  
 
Cytotoxicity test of AuNPZwit complexes 
  MCF-7 cells were seeded at 20,000 cells in 0.2 ml per well in 96-well plates 24 h prior 
to the experiment. The old medium were replaced by different concentrations of TAF, 
LAP, AuNPZwit-TAF, AuNPZwit-LAP, and AuNPZwit in serum containing medium 
and incubated for 24 h at 37 °C in a humidified atmosphere of 5 % CO2. The cells were 
then completely washed with PBS buffer three times and 10 % Alarmar blue of serum 
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containing medium was added to each well and further incubated at 37 ºC for 3 h. The 
cell viability was then determined by measuring the fluorescence intensity at 570 nm 
using a SpectraMax M5 microplate spectrophotometer. Curves were fitted by DoseRep 
function in Origin 8. 
 
Confocal laser scanning microscopy 
  MCF-7 cells were seeded in 35 mm Petri dish (Mat Tek Corporation, MA) at 50,000 
cells in 1 mL of serum containing medium 24 h prior to the experiment. The medium was 
replaced by serum containing medium and AuNPZwit-Bodipy to a final concentration of 
1 μM and were incubated for 2 h. Cells were washed with PBS three times before being 
imaged under a confocal microscope (Zeiss LSM510 meta confocal microscope equipped 
with an argon-HeNe laser, λex = 488 nm).  
 
ICP-MS Instrumentation 
All ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating 
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15 
L/min; nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 197Au; dwell time: 50 ms; 
nebulizer: cross flow; spray chamber: Scott. 
 
ICP-MS sample preparation and measurements29 
AuNPZwit-Boidpy and AuNPTTMA-Bodipy (1 M) was incubated with pre seeded 
MCF-7 cell line in 24 well plates (200,000 cells/well) for 4h and 24 h (Figure 2.10). After 
incubation and lysing the cells, the resulting cell lysate was digested overnight using 3 
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mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of aqua regia, which is highly 
corrosive and must be use with extreme caution, was added, and then the sample was 
allowed to react for another 2-3 h. The sample solution was then diluted to 100 mL with 
de-ionized water, and aqua regia. The final AuNP sample solution contained 5% aqua 
regia. The AuNPs sample solution was measured by ICP-MS under the operating 
conditions described above. Cell uptake experiments with each AuNP were repeated 3 
times, and each replicate was measured 5 times by ICP-MS. A series of gold standard 
solutions (20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb) were prepared before each experiment. Each 
gold standard solution contained 5% aqua regia. Each standard solution was also 
measured 5 times by ICP-MS using the operating conditions described above. The 
resulting calibration line was used to determine the gold amount in taken up by the cells 
in each sample. A ~100 ppm solution of dithiothreitol was used to wash the instrument 
between analyses to facilitate gold removal. 
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Figure 2.10  ICP-MS measurement of AuNPZwit-Boidpy and AuNPTTMA-Bodipy for 4 
and 24 h. 
 
TEM preparation for AuNPZwit complexes and fixed cell treated with AuNPs 
  MCF-7 cells were seeded and incubated on 15 mm diameter Theramanox® coverslips 
(Nalge Nunc International, NY) placed in 24 well plates at amount of 100,000 cells in 1 
ml of serum containing medium for 24 h prior to the experiment. The medium was 
replaced by 1 ml of serum containing medium and AuNPZwit-Bodipy or AuNPTTMA to 
a final concentration of 1 μM and incubated for 4 h.30 The medium containing the gold 
nanoparticles not taken up by the cells was discarded, and the cells were completely 
washed with PBS buffer three times. The cells were then fixed in 2 % glutaraldehyde 
with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 30 min and then 
washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. They were 
postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate buffer 
solution (pH 7.0) for 1 hr and the rinsed with distilled water three times. They were 
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dehydrated in a graded series of acetone (10 % step), and embedded in epoxy resin. The 
resin was polymerized at 60 °C for 48 h. Ultrathin sections (50−70 nm) obtained with a 
Reichert Ultracut E Ultramicrotome were stained with 2% aqueous uranyl acetate and 2% 
aqueous lead citrate and imaged under a JEOL 100S electron microscopy.  
  TEM samples of AuNPZwit and AuNPZwit complexes were prepared by placing one 
drop of the desired AuNP solution (3 μM) on to a 300-mesh Cu grid coated with carbon 
film. These samples were analyzed and photographed using the same instrument. TEM 
image of AuNPZwit is shown in Figure 2.11 (a). The average diameter of Au core is 2.5 
± 0.4 nm. 
 
 
 
Figure 2.11 (a) TEM images of AuNPZwit. (b) UV-vis spectrum of AuNPZwit and 
AuNPZwit complexes. No red shift of plasmon absorption band was observed. 
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Thermogravimetric analysis (TGA) 
 TGA was performed using a TGA 2950 high-resolution thermo-gravimetric analyzer 
(TA Instruments, Inc., New Castle, DE), which was equipped with an open platinum pan 
and an automatically programmed temperature controller. The TGA data were obtained 
as follows: about 3.0 mg of AuNPZwit was placed in the TGA pan and heated in a 
nitrogen atmosphere at a rate of 10 °C / min up to 600 °C. TGA curve of AuNPZwit is 
shown in Figure S5. The TGA data showed that the weight percentage of organic ligands 
and Au core of AuNPZwit is 35 % and 65 %, respectively. Accordingly, the average 
number of the lignads is estimated as ~100, which is comparable to the literature.31  
 
 
 
 
Figure 2.12 Thermal gravimetric analysis (TGA) data of AuNPZwit.  
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CHAPTER 3 
 
 
 
 
TUNING PAYLOAD DELIVERY IN TUMOR CYLINDROIDS USING GOLD 
NANOPARTICLES 
 
 
3.1 Introduction 
Inefficient delivery limits the efficacy of many chemotherapeutic treatments.1, 2, 3, 
4,  5 Overcoming delivery limitations requires precise control of interstitial diffusion and 
cellular uptake. Tumors typically have irregularly formed vasculature, with large 
intervessel distances and heterogeneous populations of cells.6 These populations are often 
unresponsive to standard therapy because of their distance from blood vessels and 
resistance to molecular uptake.7 This limited efficacy prevents complete cell clearance 
per drug cycle, which can eventually lead to tumor regrowth, metastatic disease and poor 
treatment outcomes.8, 9  
 Colloidal gold nanoparticles have great potential to overcome delivery limitations 
because of their biocompatibility, low toxicity, small size and tunable surface 
functionalities. 10 , 11  Functionality can be tuned by modifying the composition of 
functional molecules in the mixed monolayer on the surface of gold nanoparticles. 12, 13, 14 
In cancer cell cultures, surface properties have been shown to regulate cellular uptake, 
intracellular release and distribution in subcellular compartments.15, 16, 17, 18 Modification 
of the surface properties of gold nanoparticles therefore has the potential to control 
accumulation in tumors, and the locations at which drug payloads are released. 
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Three-dimensional in vitro tumor models provide an important tool for the 
optimization of efficient intratumoral drug delivery. Multicellular tumor cylindroids 
provide a unique platform with which to systematically monitor extracellular diffusion, 
cellular uptake and molecular release from nanoparticles in real time (Figure 3.1a). 
Tumor cylindroids are spheroids constrained between two parallel surfaces.19 , 20  The 
geometry of cylindroids allows only radial diffusion from the peripheral edge to the 
centre, simplifying analysis. Through the optically accessible cross-section, local 
concentrations of nanoparticles and dyes can be measured with standard fluorescence 
microscopy. Importantly, cylindroids consist of heterogeneous cell populations arranged 
relative to their distance from the peripheral edge: cells in the periphery are 
predominantly proliferating, and cells in the centre are mostly apoptotic and necrotic. 21, 22, 
23 This radial organization mimics the distribution of cells around blood vessels in tumors 
in vivo (Figure 3.1b).24, 25  
We predict that different surface charges can control the penetration of 
nanoparticles and the location of cellular uptake and release. Thioalkylated fluorescein-
labelled gold nanoparticles (2 nm core diameter, 6 nm overall with ligand) with positive 
and negative surface charges were synthesized (Figure 3.1c) and administered to 
cylindroids. Fluorophore concentrations were measured as functions of time and radial 
position. The diffusion of gold nanoparticles in an extracellular matrix (Matrigel) was 
measured in a linear cell free chamber. A mathematical model was developed to 
discriminate between fluorescence from particles and released fluorescein, and to 
calculate the rates of cellular uptake/release (Figure 3.1d) as a function of position in the 
cylindroids. The determined parameters were used to predict the dynamics of particle 
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transport and release from blood vessels in a conceptualized tumor (Figure 3.1b). Positive 
and negative gold nanoparticles conjugated with doxorubicin (DOX) were similarly 
synthesized, and our results show that surface charge can be used to control tissue 
penetration and drug release. This work has been reported as an article in Nature 
Nanotechnology.26  
 
Figure 3.1 Schematic showing the delivery of payload by gold nanoparticles. (a) 
Delivery of payload (green ovals) into tumor cylindroids by gold nanoparticles. Cells 
containing released FITC–SH are in green. Viable cells are shown with smooth, solid 
boundaries, and necrotic cells have irregular, dashed boundaries. Dashed arrows indicate 
diffusion and cellular uptake. In cylindroids, nanoparticles are present in the medium 
outside the boundary of the cell mass. (b) Intratumoral delivery by gold nanoparticles 
following extravasation from the vessel lumen (red circles). (c) Mixed monolayer-
protected gold nanoparticles loaded with thioalkylated FITC or doxorubicin (DOX). (d) 
Cellular uptake and FITC–SH release by thiol-mediated replacement reactions.  
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3.2 Results and discussion  
3.2.1 Uptake of fluorescent gold nanoparticles  
Nanoparticles were synthesized with gold cores protected by mixed monolayers27 
to provide tunable probes for delivery. The monolayers on these particles consisted of 
thioalkylated fluorescein isothiocyanate (FITC–SH) and either thioalkyl tetra(ethylene 
glycol) lyated trimethyl ammonium or thioalkyl tetra(ethylene glycol)-lyated carboxylic 
acid to create cationic (p-FITC–AuNP) and anionic (n-FITC–AuNP) gold nanoparticles 
(Figure 3.1c), respectively.28 The surface zeta potentials of p-FITC–AuNP and n-FITC–
AuNP were measured to be + 30 and - 36 mV, respectively. The fluorescence intensities 
of p-FITC–AuNP, n-FITC–AuNP and free fluorophore (FITC–SH) were used to calibrate 
the fluorescence intensity and determine the FITC-SH loading ratio on each gold core. 
Fluorescence intensities were linearly proportional to concentration (Figure 3.2a). 
Conjugation to gold cores quenches FITC–SH fluorescence. Treatment with potassium 
cyanide to recover quenched fluorescence increased the intensities of the p-FITC–AuNP 
and n-FITC–AuNP solutions by factors of 4 and 2.4, respectively (Figure 3.2a). The ratio 
of released ligand to free ligand fluorescence indicates that the loading ratios were 7.5 
and 8.3 for p-FITC–AuNP and n-FITC–AuNP, respectively. The linear relationship 
between intensity and concentration indicates that self-quenching did not have a large 
effect over this concentration range. 
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Figure 3.2 Fluorescence calibration and cellular uptake and release of FITC–AuNPs. (a) 
Normalized fluorescence intensities plotted against nanoparticle concentration. Dotted 
lines represent linear least-squares fitting results. For all components, fluorescence 
intensity was linearly proportional to concentration. (b) and (c) Differential interference 
contrast (DIC) and confocal green fluorescent images of cells in monolayer culture 
incubated with cationic (b) and anionic (c) gold nanoparticles. Scale bars, 50 mm.  
 
In monolayer cell culture, all FITC–SH release from nanoparticle core was 
intracellular (Figure 3.2b and c). Intracellular release of FITC–SH is mediated by 
cytoplasmic thiol compounds, of which reduced glutathione (GSH) is the most abundant. 
29 Similar selectivity would be observed in vivo, because the intracellular concentration of 
glutathione (1–10 mM) is considerably higher than that in plasma (2 µM).30, 31 After 
removal of media containing FITC–AuNP, stronger green fluorescence was observed 
across the cells treated with p-FITC–AuNP (Figure 3.2b) compared with n-FITC–AuNP 
(Figure 3.2c). This observation indicates that cellular uptake and dissociation were 
greater for cationic gold nanoparticles, potentially mediated by interactions of the 
particles with serum proteins. Cellular uptake and release in cylindroids was dependent 
on particle surface charge and radial position (Figure 3.3). Intra- and extracellular 
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fluorescence was measured in cylindroids in real time using fluorescence microscopy 
(Figure 3.3a,c, and e). A clear morphological boundary could be observed between the 
inner and outer regions of the cylindroids (Figure 3.3a, c, and e), which have been shown 
to contain viable and apoptotic microenvironments, respectively. In the outer region, 
cationic particles produced more fluorescence than free FITC and anionic particles 
(Figure 3.3a–f). For positive particles, the fluorescence intensity in the outer region 
increased with time, and eventually the entire cylindroid became fluorescent (Figure 3.3a 
and b). For negative particles, the fluorescence intensity in the outer region did not 
increase (Figure 3.3c) and remained unchanged after 11 h (Figure 3.3d). This preferential 
uptake of cationic gold nanoparticles by proliferating cells was similar to the difference 
observed in the monolayer cultures (Figure 3.2b,c). In the inner region, fluorescence 
appeared at earlier time points than in the outer region and appeared regardless of surface 
charge (Figure 3.3a–d). Images acquired at 4 and 8 h were spatially similar but fainter 
than those at 11 h. In cylindroids incubated with free FITC, strong fluorescence appeared 
only in the inner region (Figure 3.3e), and the intensity profiles remained unchanged for 
11 h after treatment (Figure 3.3f). The enhanced cellular uptake of positive particles by 
proliferating cells may be caused by electrostatic interaction with the net negative surface 
charge of the plasma membrane,32, 33 which has also been observed in liposomal and 
polymeric delivery systems. 34 , 35 , 36  Particle charge had a pronounced effect on the 
dynamics of particle uptake and fluorophore release (Figure 3.3g and h). These dynamics 
were observed by averaging the behavior in the inner and outer regions, which were 
defined as annuli 175–200 mm from the centre and 25–50 mm from the periphery of 
three cylindroids (grey bars in Figure 3b and d).  
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Figure 3.3 Release of FITC–SH from AuNPs in tumour cylindroids. (a)–(f), Green 
fluorescence images ((a), (c), and (e)) and corresponding intensity profiles ((b), (d), and 
(f)) of cylindroids treated with nanoparticles. Fluorescence images were acquired after 
incubation with p-FITC–AuNP (a), n-FITC–AuNP (c) and FITC (e) for 11, 21 and 46 h. 
Dotted circles indicate cylindroid edges. Scale bar, 300 mm. Fluorescence intensity 
profiles are shown at 11, 21, 38 and 46 h ((b) and (d)). (g) and (h), Change of average 
fluorescence intensities over time in the inner and outer regions of the cylindroids 
(indicated by grey bars in (b) and (d)) after incubation with p-FITC–AuNP (g) and n-
FITC–AuNP (h). Errors are standard error of the mean (n=3). (i) Blue fluorescence image 
of a cylindroid incubated with OPA for 18 h. Scale bar, 200 mm. (j) Green confocal 
fluorescence microscope image of the outer region of the cylindroid treated with p-FITC–
AuNP. Scale bar, 20 µm. 
 
In cylindroids treated with positive particles, fluorescence intensities increased 
monotonically (Figure 3.3g). The behavior was considerably different for cylindroids 
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treated with negative particles, in which the fluorescence intensity saturated with time 
and eventually reached a plateau (Figure 3.3h). Comparing inner and outer regions, the 
time-dependent behavior of cellular uptake/release was functionally similar for both 
particle types (Figure 3.3g and h). Two possible causes for the early appearance of 
fluorescence at the centre of the cylindroids following nanoparticle administration 
(Figure 3.3a–d) can be suggested: first, an increased rate of uptake by apoptotic/necrotic 
cells or, second, an increased rate of fluorophore dissociation due to higher thiol 
concentrations. The dye o-phthaldialdehyde (OPA) reacts non-enzymatically with amino 
acids and their derivatives in the presence of thiol compounds; this has been widely used 
to measure intracellular glutathione concentration.37, 38 Staining with OPA showed that 
the concentration of thiol compounds was higher in the outer region and decreased 
toward the centre of the cylindroids (Figure 3.3i). This location of cellular thiol 
compounds was opposite to the pattern of fluorescence from nanoparticles (Figure 3.3a–
d). We have previously shown that centers of cylindroids are composed of apoptotic and 
necrotic cells and these cells preferentially take up particles when compared to viable 
cells because they have lost membrane integrity. Together, these observations 
demonstrate that cellular uptake is the dominant mechanism. If dissociation, and not 
uptake, were the limiting mechanism, then fluorescence from released fluorophore would 
have been greater in the periphery than in the centre. Ligand dissociation was expected to 
be entirely intracellular because of the higher levels of glutathione relative to the 
extracellular environment. Confocal microscopy was used to verify that extracellular 
dissociation did not occur (Figure 3.3j). Following incubation with nanoparticles for 36 h, 
FITC–SH release was observed primarily inside cells (Figure 3.3j). Intracellular 
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localization of dissociation was consistent across the diameter of the cylindroids; 
fluorescence was observed only inside cells in both the inner and outer regions. 
Furthermore, the observed fluorescence patterns were conserved in the z-direction (away 
from the objective), supporting the use of epifluorescent microscopy for quantitative 
penetration measurements. 
 
3.2.2 Uptake of doxorubicin nanoparticles  
To further probe the potential therapeutic applications of engineered 
nanoparticles, we fabricated particles featuring a doxorubicin prodrug tethered through an 
acid-labile hydrazone linkage to a thiol ligand (Figure 3.1c). Similar to FITC–AuNP, a 
positive surface charge dramatically enhanced uptake of DOX–AuNP into proliferating 
peripheral cells when compared to negative particles and free drug (Figure 3.4). In 
cylindroids, positive particles delivered more doxorubicin than negative particles (Figure 
3.4a and b). With regard to position, positive particles delivered significantly more 
doxorubicin to viable cells in the cylindroids periphery when compared to negative 
particles and free drug, which were preferentially taken up by dead cells at the 
cylindroids centre (P < 0.05; Figure 3.4d). This charge-dependent localization was 
consistent over the 46 h of the experiment (P < 0.05; Figure 3.4e), during which the 
concentration of particles and free drug increased within the cylindroids (Figure 3.4a–c, 
radial profiles). The similarity of these results with the FITC results (Figure 3.3) supports 
the prediction that nanoparticles with positive surface charges will outperform negative 
particles for most applications, and confirms that charged gold nanoparticles have the 
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potential to overcome drug penetration barriers and deliver clinically relevant anticancer 
drugs. 
 
Figure 3.4 Doxorubicin release in cylindroids. (a)–(c), Red fluorescence images and the 
corresponding radial intensity profiles of cylindroids treated with positive DOX–AuNP 
(a), negative DOX–AuNP (b), and free DOX (c). Dotted circles indicate cylindroid edges. 
Scale bars, 200 mm. (d) and (e), Ratio of average fluorescence intensities in the outer 
region to those in the inner region of the cylindroids, 30 h after treatment (d) and as a 
function of time (e). Errors are standard error of the mean, and significance was 
determined using Student’s t-test (*P < 0.05; n = 3). 
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3.2.3 Diffusion of nanoparticles in matrix material   
In addition to regulating cellular uptake, surface charge also significantly affects 
the diffusivity of gold nanoparticles in the extracellular matrix. Diffusivity in the 
extracellular matrix was modeled using a cell-free diffusion chamber, which confined 
Matrigel between a trench cut in a polycarbonate block and the bottom surface of a well 
plate (Figure 3.5a). In this model, diffusion occurred in only one direction: from the 
exposed surface to the center of the trench. Concentrations of FITC and FITC–AuNP 
were measured as a function of time and location by acquiring a series of fluorescence 
images along the longitudinal direction every 2 h. Intensity gradients decreased from the 
edge towards the centre of the Matrigel trench, and the slope of the gradients diminished 
with time (Figure 3.5b and c). Diffusion coefficients were determined by nonlinear least-
squares fitting of the intensity gradients to a Fickian diffusion model (Figure 3.5c). The 
diffusion coefficient for FITC was (42 ± 2) × 10-7 cm2 s-1, which was larger than both 
gold nanoparticles by an order of magnitude (Figure 3.5d). Simulations with this 
diffusion coefficient matched the concentration profiles seen in the cylindroids (Figure 
3.3), suggesting that diffusion alone controlled the delivery of free FITC. Anionic gold 
nanoparticles had a larger diffusion coefficient, (9.0 ± 0.1) × 10-7 cm2 s-1, than cationic 
nanoparticles, (7.6 ± 0.1) × 10-7 cm2 s-1 (P < 0.005; n = 3; Figure 3.5d). The lower 
diffusion coefficient of positive particles suggests that electrostatic interactions with 
negatively charged macromolecules in the matrix slowed particle diffusion. The major 
components of the extracellular matrix in tumors and spheroids are collagen and 
proteoglycans. 39 , 40 , 41  Matrigel is derived from tumor matrix materials, 42  which are 
negatively charged under physiological conditions. Because cationic and anionic particles 
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have similar molecular weights and hydrodynamic radii, it is likely that electrostatic 
interactions with the matrix are the primary cause of the difference between the diffusion 
coefficients. Three mechanisms control the timing and location of drug delivery into 
tumors using nanoparticles: diffusion, cellular uptake and ligand dissociation. Our results 
indicate that, of the three, cellular uptake is the dominant mechanism. In all cylindroids, 
fluorescence appeared early in their centers (Figure 3.3). If diffusion were the limiting 
mechanism, fluorescence would first appear at the outside edge and progress into the 
center. The measured diffusion coefficients in the matrix material (Figure 3.5d) confirm 
that diffusion can account for the rapid appearance of particles in the cylindroid centers. 
 
Figure 3.5   Effect of surface charge on diffusivity through extracellular matrix material. 
(a) Schematic representation of loading module filled with Matrigel. (b) Green 
fluorescence images acquired from the bottom of the loading module 4 and 24 h after 
adding particles. Dotted lines at both ends indicate the Matrigel edges. Scale bar, 500 
mm. (c) Fluorescence intensity profiles in Matrigel along the x-axis as a function of time 
(symbols) and intensity profiles generated by fitting to a Fickian diffusion model (solid 
lines). (d) Comparison of diffusion coefficients of FITC, cationic and anionic gold 
nanoparticles in Matrigel (*P < 0.005; n = 3).  
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3.2.4 Modeling diffusion and cellular uptake/release   
A descriptive mathematical model was developed to interpret the coupled effects 
of extracellular diffusion (Figure 3.1b) and cellular uptake/release (Figure 3.1d) on 
molecular nanoparticle delivery. The model framework was designed to show how 
dynamic nanoparticle measurements in cylindroids provide preliminary information 
about nanoparticle behavior under physiological conditions. The model consisted of two 
transient partial differential equations, one for gold nanoparticles, and the other for free 
intracellular fluorophore. Concentration profiles for particles and released ligand were 
predicted using in vitro calibrations of ligand release (Figure 3.2a). Based on confocal 
microscopy results (Figure 3.3j), all ligand dissociation was modeled as an intracellular 
reaction. Internalization of FITC–AuNPs and release of FITC–SH were modeled as a 
single reaction with radially dependent forward (k1) and reverse (k2) rate constants 
(Figure 3.1d). Nanoparticle diffusion coefficients were derived from measured 
diffusivities in Matrigel (Figure 3.5). The modeling results fit the experimental data well, 
and predict that positively charged particles will outperform negative particles for most, 
but not all applications (Figure 3.6). The modeling results (solid lines in Figure 3.6a and 
b) capture a number of key characteristics of the fluorescent patterns shown in Figure 3.3 
and the experimental data points (symbols, Figure 3.6a and b). First, a higher 
fluorescence was observed in the inner regions than in the outer at early time points. 
Second, positive particles showed a monotonic increase in fluorescence, and this increase 
was more pronounced in the outer regions. Third, negative particles displayed saturation 
of fluorescence. By separating the fluorescence contributions from free and bound 
fluorophore, the modeling results indicate that particle diffusion was rapid, and the 
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appearance of free fluorophore by uptake and dissociation controlled overall fluorescence 
(Figure 3.6c). Calculated kinetic rates suggest that viable cells had a higher net uptake of 
positive particles because of a lower export rate (k2) in both inner and outer regions (P < 
0.05; n = 3; Figure 3.6d). For negative particles, the forward rate constant was only larger 
in the inner region (P < 0.05; n = 3; Figure 3.6d). Modeling predictions were based on a 
hypothetical tumor for which the geometry was inverted: particles diffused from a blood 
vessel (0 < r < 5 µm) into tumor tissue (r > 5 µm). Because of their greater diffusion 
coefficient, negative particles penetrated deeper into the interstitium at all times (Figure 
3.6e). However, the concentration of released intracellular ligand was greater for positive 
particles, because of their larger net uptake rate (Figure 3.6f). This predicts that deep 
penetration of negative particles may be mitigated by the elevated interstitial fluid 
pressures often observed in tumors in vivo.43, 44, 45 For both particles, the concentration of 
released ligand reached a maximum between 20 and 30 h (Figure 3.6f). Regions of 
proliferating (10–70 µm) and quiescent (75–120 µm) cells were defined based on single 
cell analysis performed in cylindroids. The average concentrations of released ligand for 
positive particles in the proliferating and quiescent regions were more than 11-fold and 8-
fold greater at all times, respectively (Figure 3.6g). Deep in the tissue (> 1 mm) the 
concentration of released ligand was greater for negative particles at later times (> 20 h; 
Figure 3.6h). These results suggest that positive particles will release more ligand to most 
cells at all times (Figure 3.6f and g) and therefore would be advantageous for most 
applications. Complementarily, negative particles would have an advantage in delivering 
drugs deep into tissue (Figure 5d and figure 6h) and would be useful for treating tumors 
with large intervessel spacing and high hypoxic tolerance. 
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Figure 3.6 Rate constants of cellular uptake and predictions of particle and ligand 
distribution in tumors. (a) and (b) Fluorescence intensity profiles measured in 
fluorescence images of cylindroids (symbols) and those predicted by the mathematical 
model (solid lines). Concentrations were normalized by the maximum concentration of 
FITC–AuNP in the cylindroids. (c) Independent concentration profiles of fluorophore 
bound to nanoparticles (FITC–AuNP) and released fluorophore ligand (FITC–SH) 
predicted by the computation model. (d) Comparison of forward (k1) and reverse (k2) rate 
constants in different regions. Errors are standard error of the mean, and significance was 
determined using Student’s t-test (*P < 0.05). (e) and (f) Modeled concentrations of 
FITC–AuNPs and released FITC–SH as a function of distance from blood vessels of a 
hypothetical tumor. Clearance half-life of FITC–AuNPs was assumed to be 3 h. (g) 
Average concentrations of FITC–AuNPs in the regions 10–70 µm (proliferating) and 75–
120 µm (quiescent) from the blood vessel wall as a function of time. (h) Average 
concentrations of released FITC in deep tumor regions (1.0–1.5 mm) as a function of 
time.  
 
3.3 Summary and future outlook  
Using a combination of experimental in vitro tumor models and mathematical 
modeling, we have shown that, under most circumstances, positively charged 
nanoparticles improved delivery of payloads to the majority of cells in tumors, whereas 
negatively charged particles would perform better when delivering drugs deep into 
tissues. Positive particles had significantly higher uptake and dissociation by viable cells, 
whereas negative particles diffused at a faster rate. Both positive and negative particles 
penetrated tissues rapidly, and for both, the rate of cellular uptake and dissociation was 
slower than extracellular diffusion. The mathematical models suggested that the rate of 
cellular uptake of both particles was fast in apoptotic and necrotic tissues. Furthermore, 
the uptake kinetics of positive particles is irreversible, but is reversible for negative 
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particles over the timescales investigated. The ability to tune surface charge to control 
tissue penetration and drug release makes gold nanoparticles a flexible and powerful drug 
delivery vehicle. 
 
3.4 Synthesis of materials and experimental methods  
3.4.1 Synthesis of ligand and fabrication of nanoparticle   
 
Figure 3.7 Synthetic procedure of the thioalkylate tetra (ethylene glycol) FITC and Dox 
conjugated ligands (a) 1. methanesulfonyl chloride, TEA, DCM, RT, 4h, 2. sodium azide, 
DMF, 4h. (b) triphenylphosphine, THF. (c) fluorescein isothiocyanate, acetone. (d) TFA, 
TIPS, DCM, RT, 4h, (e) hydrazine, MeOH, reflux. (f) Doxorubicin, MeOH 
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Synthesis of compound 2  
  Compound 2 Trityl protected thioalkyl tetra (ethylene glycol) alcohol 1 (5 g, 8.02 
mmol)[2] was dissolved in dry dichloromethane (80 mL) that was placed in an ice bath. 
When the temperature reached about 0 °C, triethylamine (1.67 mL, 12.03 mmol) and 
methanesulfonyl chloride (1.25 mL, 16.04 mmol) were added successively. The mixture 
was stirred at room temperature for 4 h. The reaction mixture was evaporated to yield the 
crude product (5.72 g). The crude mesylated compound was then dissolved in dry 
dimethyl formamide (30 mL). Subsequently, sodium azide powder (1.04 g, 16.04 mmol) 
was added to the solution. The mixture was stirred at 80 oC for 4 h. After cooling to room 
temperature, the solution was poured into 100 mL ice-water. The mixture solution was 
extracted by CH2Cl2 (3 x 25 mL). The organic phases were combined and washed with 
brine. The crude product was charged on a silica gel chromatographic column with ethyl 
acetate as eluent for purification. Yields were around 88 %.  1H NMR (400 MHz, CDCl3, 
TMS): δ 7.41 (m, 6H, HAr), 7.27 (m, 6H, HAr), 7.20 (m, 3H, HAr), 3.68 (m, 12H, 
−OCH2−), 3.58 (m, 2H,−CH2O−), 3.44 (t, 3J = 6.8 Hz, 2H, −CH2O−), 3.37 (t, 3J = 5.0 Hz, 
2H, −CH2O−), 2.13 (t, 3J = 7.4 Hz, 2H, −SCH2−), 1.57 (m, 2H, −CH2−), 1.38 (m, 2H, 
−CH2−), 1.20 (m, 14H, −CH2−). 
  
Synthesis of compound 3 
  A mixture of Trityl protected tetra (ethylene glycol) azide 2 (2.0 g, 3.08 mmol) and 
triphenylphosphine (0.97 g, 3.69 mmol) were dissolved in tetrahydrofuran (20 mL). After 
that, water (0.5 mL) was added to the solution mixture. The mixture was stirred at room 
temperature for 12h. The mixture was poured into water. The aqueous suspension was 
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extracted by dichloromethane (3 x 25 mL) and washed thoroughly with brine and dried 
over anhydrous magnesium sulfate. After filtration, the combined organic phase was 
evaporated to provide a white solid. The crude mixture was charged on silica gel column 
with methanol:dichloromethane:ammonium hydroxide (50:45:5) as eluent for purification 
to yield compound 3 (1.39 g, 73%) 1H NMR (400 MHz, CDCl3, TMS): δ 7.40 (m, 6H, 
HAr), 7.27 (m, 6H, HAr), 7.17 (m, 3H, HAr), 3.66 (m, 10H, −OCH2−), 3.58 (m, 
2H,−CH2O−), 3.50 (t, 3J = 5.16 Hz, 2H, −CH2O−), 3.44 (t, 3J = 6.68 Hz, 2H, −CH2O−), 
2.12 (t, 3J = 7.3 Hz, 2H, −SCH2−), 1.56 (m, 2H, −CH2−), 1.38 (m, 2H, −CH2−), 1.22 (m, 
14H, −CH2−). MS (ESI): m/z 622.5 [M++H] (calcd for 622.4). 
 
Synthesis of compound 4 and 5  
  To a stirred solution of trityl protected tetra (ethylene glycol) amine 3 (1.0 g, 1.60 mmol) 
in dry acetone (ca. 10 mL) was subsequently added Fluorescein isothiocyanate (FITC) 
(0.543 g, 1.33 mmol). After stirred for 6 h at room temperature, the reaction mixture was 
evaporated to remove acetone. The crude product 4 was then dissolved in dry 
dichloromethane (ca.10 mL) and stoichiometric trifluoroacetic acid (2.5 mL) was added 
under stirring. Subsequently, triisopropylsilane (0.65 mL, 3.20 mmol) was added. The 
reaction was allowed to proceed at room temperature for 12 h. The solvent and excess 
trifluoroacetic acid and triisopropylsilane were removed under reduced pressure. The 
product 5 was confirmed by mass spectrometry without purification. MS (ESI): m/z 
769.4 [M++H] (calculated for 769.3). 
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Synthesis of compound 7 
A mixture of hydrazine (1.37 g, 43 mmol) and compound 6 (1.0 g, 4.30 mmol) were 
dissolved in methanol (5 mL). After stirring for 3h at 70 °C, the solvent was removed 
under reduced pressure. The crude product was then poured into a mixture of 
dichloromethane and distilled water. Organic layer was separated and concentrated at 
reduced pressure to afford compound 7 as a white powder. (0.78 g, 78 %) 1H NMR (400 
MHz, CDCl3, TMS): δ 6.98 (s, 1H, -NH-), 3.90 (s, 2H, -NH2), 2.50 (q, J = 7.2 Hz, 2H, 
HS-CH2-), 2.50 (q, J = 7.3 Hz, 2H, -CH2-CO-), 1.55 (m, 2H, −CH2−), 1.25 (m, 14H, 
−CH2−). 13C NMR (100.64 MHz, CDCl3, TMS) δ 174.05, 34.57, 34.01, 29.42, 29.36, 
29.25, 29.02, 28.33, 25.49, 24.65. 
 
Synthesis of compound 7, Dox-SH  
A methanol solution of compound 7 (0.03 g, 0.13 mmol) and doxorubicin (0.05 g, 0.08 
mmol) was stirred overnight at 60 °C under argon. The reaction mixture was concentrated 
and precipitated into hexane/ethyl acetate (1:2, v/v). The product was further purified by 
washing with hexane and ethyl acetate to give compound 8 as a red solid. (0.04 g, 61 %) 
The product was confirmed by mass spectrometry. MS (ESI): m/z 758.5 [M++H] (calcd 
for 757.89). 
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Synthesis of mixed monolayer-protected gold nanoparticles  
   Pentanethiol coated gold nanoparticles (2 nm in diameter) were synthesized according 
to the method reported by You et. al.46 The synthetic procedure of the thioalkylate tetra 
(ethylene glycol) fluorescein isothiocyanate (FITC) and doxorubicin (Dox) conjugated 
ligands is represented in Scheme S1 and the details of each reaction step are as follows: 
 
FITC-AuNP fabrication  
  The cationic and the anionic nanoparticles with FTIC conjugations were afforded by 
adding 20 mg of 1-pentanethiol coated gold nanoparticles in dichloromethane into the 
dichloromethane-methanol mixtures of 5mg thioalkylate tetra (ethylene glycol) FITC 
conjugated ligands (FITC-SH) and 50 mg thiolalkyl tetra (ethylene glycol)lyated 
trimethyl ammonium ligand (TTMA) or 50 mg thiolalkyl tetra (ethylene glycol)lyated 
carboxylic acid ligand (TCOOH), respectively. The mixture were then stirred at room 
temperature for 2~3 days. After all the solvents are evaporated, the ligand-exchanged 
nanoparticles were washed thoroughly with hexanes, diethyl ether and dichloromethane 
to remove all the free ligands and were collected by centrifugation. The nanoparticles 
were dried under high vacuum. The absence of free ligands were confirmed by 1H-NMR. 
 
Fluorescence calibration and loading ratios  
  Fluorescence intensities of p-FITC-AuNP, n-FITC-AuNP and FITC-SH were measured 
at 0.5 and 1.0 M in DMEM by fluorimetry (SPECTRAmax GEM　 INI XS, Molecular 
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Devices) to calibrate fluorescence intensity and determine the FITC-SH loading ratio. 
The loading ratio is the number of conjugated FITC ligands per gold core. Conjugation to 
the gold cores quenches FITC-SH fluorescence, and treatment with potassium cyanide 
rapidly reacts with the gold cores and triggers FITC-SH release. Potassium cyanide, at a 
final concentration of 20mM, was added to solutions of p-FITC-AuNP and n-FITC-
AuNP in DMEM. The solutions were incubated at 37 ºC for 4 hrs and fluorescence was 
measured by exciting at 480nm and detecting at 520nm. The ratios of fluorescence 
intensity to concentration were determined by linear regression and were subsequently 
used to convert from intensity to concentration. Quenching effects were determined by 
comparing the fluorescence intensity of the p-FITC-AuNP and n-FITC-AuNP solutions 
with and without KCN. The loading ratio was determined by dividing the 6fluorescence 
intensities of FITC ligands released from gold cores by free FITC-SH at the same 
concentrations.  
 
Dox-AuNP fabrication and characterization  
To fabricate Dox-AuNP via ligand place exchange reaction, 10 mg of 1-pentanethiol 
coated gold nanoparticles was mixed with 3 mg of Dox-SH and 27 mg of TTMA or 
TCOOH ligands in a mixture of dichloromethane (5 mL) and methanol (5 ml). The 
solution was stirred at room temperature for 24 hours. Solvent was removed by rotary 
evaporator and nanoparticles were washed with hexane and diethyl ether (20 mL x 5). 
Nanoparticles were further purified by dialysis in phosphate buffer (pH: 7.8) using 
SnakeSkin pleated dialysis tubing (10,000 MWCO) for 2 days to remove all free ligands.  
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The number of Dox-SH per particles was calculated as followings. Dox-AuNP (0.4 M) 　
was incubated at 37 °C for 24 h in buffer (pH: 2.0) solution. Dox on particle was released 
as the hydrazone linkage was completely hydrolyzed at low pH. Dox is quenched by gold 
nanoparticles and photoluminescence was only observed upon Dox release. Release of 
Dox 7was monitored using fluorimetry (Figure 3.8a). The solution was centrifuged using 
Amicon Ultra-4 tube (10,000 MWCO) to separate released Dox. Concentration of the 
filtrate was calculated based on the Beer-Lambert law (max = 490 nm) using 
spectrophotometry (Figure 3.8b). By comparing the absorbance of the filtrate with the 
absorbance before incubation, the number of Dox-SH attached on a particle was 
estimated to be 6 Dox-SH ligands per particle. The number of Dox-SH per n-Dox-AuNP 
was calculated via potassium cyanide decomposition. A 1 ml solution of 4 μM n-Dox-
AuNP in THF was added to 1 mL of a 0.1 M aqueous KCN solution, followed by brief 
agitation. After 2 hr, the plasmon absorption band of n-Dox-AuNP at 520 nm was 
completely decayed, while absorbance of Dox-SH remained. The concentration of Dox-
SH was calculated based on the Beer-Lambert law (λ = 560 nm). A molar extinction 
coefficient of Dox-SH in THF/H2O (1:1) was obtained for this estimation (ε = 9.69 x 103 
at 560 nm). By comparing with the concentration of n-Dox-AuNP before etching, the 
number of attached Dox-SH was estimated to be 5 ligands per particle. 
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Figure 3.8 (a) The Dox-AuNP released Dox at pH 2 for 24 h incubation but remained 
stable at pH 7.4. (b) Uv-spectrum of Dox-AuNP before incubation and a filtrate after 
incubation. 
 
 
3.4.2 Experimental methods  
FITC–AuNP and DOX–AuNP uptake and ligand release in monolayer culture 
  LS174T human colon carcinoma cells were grown in DMEM (1 g l-1 glucose) 
supplemented with 10% fetal bovine serum at 37 °C with 5% CO2 in a humidified 
incubator. Cells in monolayer cultures were incubated with 1 mM FITC–AuNPs for 6 h, 
and were washed with PBS three times before image acquisition. Confocal fluorescence 
microscope images were acquired with a Zeiss LSM510 microscope equipped with a ×25 
objective lens. A 488-nm argon laser was used for excitation, and emission was acquired 
at 505 nm (long pass). 
 
FITC–AuNPs and DOX–AuNPs in cylindroids  
  Cylindroids were prepared from spheroids as described previously and in the 
Supplementary Information. After equilibration, cylindroids were treated with 125 mM 
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FITC, 1 mM FITC–AuNP, 1 mM DOX, or 1 mM DOX–AuNP. Transmitted and 
fluorescence images were acquired with an Olympus IX71 microscope with a ×10 
objective at 0, 11, 21, 38, 46 h after treatment. Radial fluorescence intensity profiles in 
the cylindroids were generated using a customized script in ImageJ (NIH Research 
Services Branch). Average fluorescence intensities were determined for two annular 
regions: 175–200 mm from the centre (inner) and 25–50 mm from the periphery (outer). 
For confocal fluorescence microscopy, cylindroids were prepared in 35-mm glass-
bottomed culture dishes. Images were acquired with a Zeiss LSM510 microscope 
equipped with a × 63 oil-immersion objective. A 488-nm argon laser was used for 
excitation, and emission was acquired at 505 nm. 
 
Thiol compounds in cylindroids  
  The distribution of GSH was determined by measuring the fluorescence intensity of 
OPA derivatives. OPA reacts with amino acids in the presence of thiol compounds to 
form fluorescent derivatives. Cylindroids were incubated with 250 ml of 100 mM OPA in 
PBS. Transmitted and fluorescence images were acquired 4, 18 and 36 h after treatment. 
Samples were excited at 350 nm and measured at 460 nm. 
 
Extracellular diffusion of FITC–AuNP  
  Diffusion of gold nanoparticles was measured in Matrigel in a loading module (Figure 
3.5a) as described in the Supplementary Information. The loading module was prepared 
by making a channel (3.1 × 0.5 × 6.2 mm3; W × H × L) in the top of a polycarbonate 
block (9.6 × 4.8 × 6.2 mm3). Before loading, the well plate was plasma-treated for 5 min 
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and sterilized with UV for 4 h. The module was loaded with 12 ml Matrigel, which was 
allowed to gelate at 37 °C for 5 min. Pre-warmed DMEM (2.0 ml) was added to each 
well and, after 2 h, was replaced with DMEM containing 1 mMFITC–AuNP. Transmitted 
and green fluorescence images were acquired every 2 h for 36 h. Spatial concentration 
profiles were obtained by averaging pixel values across the width of the channel. 
Diffusion coefficients of FITC, p-FITC–AuNP and n-FITC–AuNP were determined by 
fitting measured fluorescence intensities to a mathematical diffusion model. Numerical 
solutions were calculated using finite elements, and best-fit diffusion coefficients were 
determined by nonlinear least-squares optimization in Matlab (MathWorks). 
 
Mathematical modelling of particle diffusion and cellular uptake in cylindroids 
  Internalization of gold nanoparticles from the extracellular space and 
glutathionemediated replacement were represented with a one-step reversible reaction: 
 
where k1 and k2 are forward and reverse reaction constants. Coupled conservation 
equations for FITC–AuNPs and released FITC–SH incorporated expressions for 
extracellular nanoparticle diffusion and the kinetics of particle uptake and ligand release: 
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From confocal measurements, the cell volume fraction fv was found to be 0.48. The 
effective nanoparticle diffusion coefficients Deff were derived from the Matrigel 
experiments. Reaction rates were assumed to be functions of position as described in the 
Supplementary Information. Thismodel was solved using finite elements and fit to 
measured fluorescence concentrations by nonlinear least-squares optimization in Matlab. 
Calculated fluorescence values were determined from the sum of the volumefraction- 
weighted particle (FITC–AuNP) and released ligand (FITC–SH) concentrations. 
Calculated rate constants were reported as average values inside the inflection point, r,Rt 
(inner) and between the inflection point and the edge, Rt < r < 1 (outer). Significance was 
determined using unpaired Student’s t-tests with unequal variance. Particle diffusion and 
ligand release was modelled in a hypothetical tumor as described in the Supplementary 
Information. In thismodel, the blood was assumed to be well mixed, and particles were 
cleared with a 3-h half-life 
 
Nanoparticle uptake into viable and dead cells in monolayer cultures  
  To measure the effects of cell viability on uptake, cells were treated with HEPES 
buffered medium (viable cells) or saline (dead cells), both containing 500 nM positive 
Dox-AuNP or 500 nM negative Dox-AuNP. Viability was confirmed using 800 nM 
Ethidium Homodimer (Eth-D1; Invitrogen, Carlsbad, CA). Samples were excited using a 
546/10 nm filter and measured through a 590 nm long pass emission filter (Chroma, 
Rockingham, VT). The increase in fluorescence intensities from 1 hour to 17 hours post 
treatment was evaluated at nine 8locations for each treatment. Values were normalized by 
the average increase in intensity of viable cells. Particle uptake was dependent on cell 
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viability (Figure 3.9). Following growth in medium or saline, cells were either viable or 
dead as confirmed by staining with ethidium homodimer, Eth-D1 (Figure 3.9). Both 
positive and negative particles were taken up viable cells, but uptake was significantly 
greater in necrotic cells. Non-viable cells have greater uptake because they have lost 
membrane integrity. 
 
Figure 3.9 Nanoparticle uptake into viable and dead cells a, b, Transmitted and red 
fluorescent images of viable (a) and dead (b) cells in monolayer culture treated with 
positive Dox-AuNP. c, Normalized fluorescence intensities of viable and dead cells 
following uptake of viability stain Eth-D1, positive Dox-AuNP and negative Dox-AuNP. 
Error bars are standard error of the mean (*P < 0.05, n=9). Scale bars are 50µm. 
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Cylindroid preparation  
  Cylindroids were formed from spheroids as described previously.5 To grow spheroids, a 
single-cell suspension was inoculated into cell culture flasks coated with poly(2-
hydroxyethyl methacrylate). After 6-8 days, cylindroids were prepared by placing 
spheroids in the 150 ± 15μm gap between the bottom of 48 well plates and 3mm diameter 
cylindrical plugs projecting from the cover. Fresh media (200 µl) was added to each well 
and cylindroids were allowed to equilibrate overnight. 
 
Image acquisition  
  Cylindroid images were acquired with an Olympus IX71 microscope with a 10X 
fluorescence objective. FITC and Dox samples were excited at 470 and 546 nm and 
measured at 525 and 590 nm, respectively. Careful attention was made during image 
acquisition to ensure that quantitative comparison was possible, including 1) maintaining 
a constant exposure time for all image acquisitions and 2) acquiring a background image 
for all cylindroids before the addition of treatment or fluorophore. Background 
fluorescence was subtracted before analysis. To cover the large size of cylindroids, 4 (2  
2) or 9 (33) individual images were acquired and tiled using a script in IPLab (BD 
Bioscience). 
 
Radial fluorescence intensity profiles  
  Radial fluorescence intensity profiles in cylindroids were generated using a customized 
script in ImageJ (NIH Research Services Branch). Cylindroid radii were determined from 
transmitted light images. Average radial intensities were obtained by summing the 
 94 
intensities of all pixels at a given radius and dividing by the number of pixels. Distances 
were normalized by the cylindroid radius and fluorescence intensities were normalized by 
the maximum fluorescence intensity. Background autofluorescence was corrected by 
subtracting the intensity profile of the fluorescence image at 0 hrs. Average temporal 
behavior was determined for the four time points by averaging all pixels in two annular 
regions: an inner region (175 - 200 μm from the center) and an outer region (25 - 50 μm 
from the periphery). 
 
Extracellular diffusion of FITC-AuNP  
  Diffusion of gold nanoparticles was measured in Matrigel in a loading module attached 
to the center of a well plate (Figure 3.5a). The loading module was prepared by making a 
channel (3.1 x 0.5 x 6.2 mm; W x H x L) in the top of a polycarbonate block (9.6 x 4.8 x 
6.2 mm). Before loading, the well plate was cleaned by plasma treatment for 5 min and 
sterilized with UV for 4hrs. Matrigel was kept at 4 ºC to prevent gelation. After loading, 
12 l added Matrigel was allowed to gelate at 37 °C for 5min. Pre　 -warmed DMEM 
(2.0ml) was added to each well. After 2hrs, the medium was replaced with fresh DMEM 
containing 1μM FITC-AuNPs. Transmitted and green fluorescence images (excitation: 
470/40nm, emission 525/50nm) were acquired every 2 hrs for 36 hrs using a 4X 
UPlanApo objective. To cover the large area of the module, four images were acquired 
and tiled using IPLab. Background autofluorescence was corrected by subtracting the 
fluorescence image taken at 0hrs from all fluorescence images. 
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Mathematical modeling of diffusion in Matrigel  
  Diffusion coefficients of FITC, p-FITC-AuNP and n-FITC-AuNP in Matrigel were 
determined by fitting measured fluorescence intensities as a function of time and location 
in the loading module (Figure 3.5a) to a mathematical model of diffusion 
 
 
with the following initial and boundary conditions 
 
 
where C is nanoparticle concentration, L is length in the x-axis direction, and f1(t) and f2(t) 
are the measured concentrations at the boundaries as functions of time. Gradients of 
diffusing components in y- and z-axis were assumed to be negligible compared to the 
gradient along the x-axis (Figure 3.5a). The model assumes that the initial concentrations 
in the matrix were zero. Particle concentrations were determined from fluorescence 
intensities using the calibration described above. Particle concentration profiles as a 
function of distance from the edge (x-axis) were obtained by averaging pixel values 
across the width (y-axis). Numerical solutions were calculated using finite elements and 
diffusion coefficients were determined by nonlinear least square optimization using 
Matlab (The MathWorks). 
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Mathematical modeling of diffusion and reaction in cylindroids  
  A mathematical model was constructed to couple particle diffusion and cellular uptake. 
Effective diffusivities were derived from measured diffusivities in Matrigel, and were 
proportional to the volume of extracellular space, 1 - fv, and inversely proportional to the 
tortuosity, which was assumed to have a value of 2.7. Internalization of gold 
nanoparticles from extracellular space and glutathione-mediated replacement were 
represented with a one-step reversible reaction. A reversible reaction was used to model 
cellular uptake and release, because it was the most likely cause of the saturation kinetics 
observed with negative particles. Reaction rates were assumed to be first order with 
respect to FITC-AuNPs and released FITC-SH. Released FITC-SH was assumed to not 
diffuse in the extracellular space. Initially neither species was assumed to be present 
throughout the cylindroid, and the symmetric boundary condition was assumed at the 
center. At the interface between the cylindroids and the culture media the measured 
particle concentrations were used as boundary conditions. 
 
Reaction rates as functions of position  
  Reaction rates were assumed to be functions of position and were modeled with a 
sigmoidal function that asymptotically approaches maximum and minimum values with a 
smooth transition. 
 
The subscript j indicates the direction of the reaction (forward, 1 or backward, 2); kjmin 
and kjmax are the minimum and maximum reaction rates; Rt is the location of the inflection; 
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and　 is the width of the transition (Figure 3.11). This equation asymptotically 
approaches kjmin and kjmax as the normalized radius, r, approaches 0 and 1, respectively 
(Figure 3.11). In figure 3.11 Rt = 0.6 and σ = 0.1. With these parameters, k is within 10-6 
of kmax at r = 0 and 10-4 of kmin at r = 1. Additionally, k is at 10% of the maximum and 
minimum values at r = 0.45 and r = 0.75. Nonlinear least square optimization determined 
kjmin, kjmax and Rt by minimizing the error between measured and calculated radial 
concentration profiles. The width of transition () was fixed at 60 m based on the 　
fluorescence images (Figure 3.3), which was less than 10% of the radius of most 
cylindroids. The location of the inflection, Rt, was found to be between 0.6 and 0.8 for all 
cylindroids. All parameters were determined for the forward and reverse reactions of both 
particle types. 
 
 
Figure 3.10 Profile of the reaction constant as a function of the radial distance from the 
center of the cylindroid. The values kmin and kmax are the maximum and minimum value of 
the sigmoidal function; Rt is the location of the inflection; and  is the width of the 
transition. 
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Modeling particle diffusion and ligand released in a hypothetical tumor  
   Particle and released ligand concentrations were predicted using the calculated 
diffusion and reaction kinetic parameters. To more closely describe tumor biology, the 
cylindrical geometry was inverted; diffusion was assumed to originate from the lumen of 
a 10 μm blood vessel. The concentration of particles in the blood was assumed to be well 
mixed and be cleared by simple two-compartment, monotonically decreasing 
pharmacokinetics. Previous measurements in mice estimated that the clearance half-life 
of PEG-coated gold nanoparticles is approximately three hours. The average released 
ligand concentration was determined in three regions as a function of time, 10-70, 75-120, 
and 1000-1500μm.  
 
 
3.5 References 
 
1. Hicks, K. O.; Pruijn, F. B.; Sturman, J. R.; Denny, W. A.; Wilson, W. R., Multicellular 
resistance to tirapazamine is due to restricted extravascular transport: A 
pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer 
Res.2003, 63 (18), 5970-5977 
2. Lankelma, J.; Dekker, H.; Luque, R. F.; Luykx, S.; Hoekman, K.; van der Valk, P.; van 
Diest, P. J.; Pinedo, H. M., Doxorubicin gradients in human breast cancer. Clin. 
Cancer Res. 1999, 5 (7), 1703-1707 
3. Minchinton, A. I.; Tannock, I. F., Drug penetration in solid tumours. Nat. Rev. Cancer 
2006, 6 (8), 583-592. 
 99 
  
 
4. Jain, R. K., Transport of molecules, particles, and cells in solid tumors. Annu. Rev. 
Biomed. Eng. 1999, 1, 241-263. 
5. Primeau, A. J.; Rendon, A.; Hedley, D.; Lilge, L.; Tannock, I. F., The distribution of 
the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. 
Cancer Res. 2005, 11 (24), 8782-8788. 
6. Vaupel, P.; Kallinowski, F.; Okunieff, P., Blood-Flow, Oxygen and Nutrient Supply, 
and Metabolic Microenvironment of Human-Tumors - a Review. Cancer Res. 1989, 
49 (23), 6449-6465 
7. Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F., Drug resistance and the solid 
tumor microenvironment. J. Natl. Cancer I 2007, 99 (19), 1441-1454 
8. Grantab, R.; Sivananthan, S.; Tannock, I. F., The penetration of anticancer drugs 
through tumor tissue as a function of cellular adhesion and packing density of tumor 
cells. Cancer Res. 2006, 66 (2), 1033-1039. 
9. Goldacre, R. J.; Sylven, B., On the Access of Blood-Borne Dyes to Various Tumour 
Regions. Brit. J. Cancer 1962, 16 (2), 306-322. 
10 . You, C. C.; Verma, A.; Rotello, V. M., Engineering the nanoparticle-
biomacromolecule interface. Soft Matter 2006, 2 (3), 190-204. 
11. You, C. C.; De, M.; Han, G.; Rotello, V. M., Tunable inhibition and denaturation of 
alpha-chymotrypsin with amino acid-functionalized gold nanoparticles. J. Am. Chem. 
Soc. 2005, 127 (37), 12873-12881. 
 100 
  
 
12. Goodman, C. M.; Chari, N. S.; Han, G.; Hong, R.; Ghosh, P.; Rotello, V. M., DNA-
binding by functionalized gold nanoparticles: Mechanism and structural requirements. 
Chem. Biol. Drug Des. 2006, 67 (4), 297-304. 
13. McIntosh, C. M.; Esposito, E. A.; Boal, A. K.; Simard, J. M.; Martin, C. T.; Rotello, 
V. M., Inhibition of DNA transcription using cationic mixed monolayer protected gold 
clusters. J. Am. Chem. Soc. 2001, 123 (31), 7626-7629. 
14. You, C. C.; De, M.; Han, G.; Rotello, V. M., Tunable inhibition and denaturation of 
alpha-chymotrypsin with amino acid-functionalized gold nanoparticles. J. Am. Chem. 
Soc. 2005, 127 (37), 12873-12881 
15 . Thomas, M.; Klibanov, A. M., Conjugation to gold nanoparticles enhances 
polyethylenimine's transfer of plasmid DNA into mammalian cells. P. Natl. Acad. Sci. 
USA 2003, 100 (16), 9138-9143. 
16. Rosi, N. L.; Giljohann, D. A.; Thaxton, C. S.; Lytton-Jean, A. K. R.; Han, M. S.; 
Mirkin, C. A., Oligonucleotide-modified gold nanoparticles for intracellular gene 
regulation. Science 2006, 312 (5776), 1027-1030. 
17. Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A., Au nanoparticles target cancer. Nano 
Today 2007, 2 (1), 18-29. 
18. Chithrani, B. D.; Chan, W. C. W., Elucidating the mechanism of cellular uptake and 
removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 
2007, 7 (6), 1542-1550. 
 101 
  
 
19. Kasinskas, R. W.; Forbes, N. S., Salmonella typhimurium specifically chemotax and 
proliferate in heterogeneous tumor tissue in vitro. Biotechnol. Bioeng. 2006, 94 (4), 
710-721. 
20. Kim, B. J.; Forbes, N. S., Flux analysis shows that hypoxia-inducible-factor-1-alpha 
minimally affects intracellular metabolism in tumor spheroids. Biotechnol. Bioeng. 
2007, 96 (6), 1167-1182. 
21. Freyer, J. P.; Sutherland, R. M., Selective Dissociation and Characterization of Cells 
from Different Regions of Multicell Tumor Spheroids. Cancer Res. 1980, 40 (11), 
3956-3965. 
22 . Kasinskas, R. W.; Forbes, N. S., Salmonella typhimurium lacking ribose 
chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 2007, 
67 (7), 3201-3209. 
23. Sutherland, R. M., Cell and Environment Interactions in Tumor Microregions - the 
Multicell Spheroid Model. Science 1988, 240 (4849), 177-184. 
24 . Kim, B. J.; Forbes, N. S., Single-Cell Analysis Demonstrates How Nutrient 
Deprivation Creates Apoptotic and Quiescent Cell Populations in Tumor Cylindroids. 
Biotechnol. Bioeng. 2008, 101 (4), 797-810. 
25. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K., Interstitial pH and pO(2) gradients 
in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. 
Nat. Med. 1997, 3 (2), 177-182. 
26. Kim, B.; Han, G.; Toley, B. J.; Kim, C. K.; Rotello, V. M.; Forbes, N. S., Tuning  
payload delivery in tumour cylindroids using gold nanoparticles. Nat. Nanotechnol. 
2010, 5 (6), 465-472. 
 102 
  
 
27. De, M.; You, C. C.; Srivastava, S.; Rotello, V. M., Biomimetic interactions of 
proteins with functionalized nanoparticles: A thermodynamic study. J. Am. Chem. Soc. 
2007, 129 (35), 10747-10753. 
28. Chompoosor, A.; Han, G.; Rotello, V. M., Charge dependence of ligand release and 
monolayer stability of gold nanoparticles by biogenic thiols. Bioconjugate Chem. 
2008, 19 (7), 1342-1345. 
29. Hong, R.; Han, G.; Fernandez, J. M.; Kim, B. J.; Forbes, N. S.; Rotello, V. M., 
Glutathione-mediated delivery and release using monolayer protected nanoparticle 
carriers. J. Am. Chem. Soc. 2006, 128 (4), 1078-1079. 
30. Jones, D. P.; Carlson, J. L.; Samiec, P. S.; Sternberg, P.; Mody, V. C.; Reed, R. L.; 
Brown, L. A. S., Glutathione measurement in human plasma Evaluation of sample 
collection, storage and derivatization conditions for analysis of dansyl derivatives by 
HPLC. Clin. Chim. Acta 1998, 275 (2), 175-184. 
31. Hassan, S. S. M.; Rechnitz, G. A., Determination of Glutathione and Glutathione-
Reductase with a Silver Sulfide Membrane-Electrode. Anal. Chem. 1982, 54 (12), 
1972-1976. 
32. Baldwin, A. L.; Wu, N. Z.; Stein, D. L., Endothelial Surface-Charge of Intestinal 
Mucosal Capillaries and Its Modulation by Dextran. Microvasc. Res. 1991, 42 (2), 
160-178. 
33. Ghitescu, L.; Fixman, A., Surface-Charge Distribution on the Endothelial-Cell of 
Liver Sinusoids. J. Cell. Biol. 1984, 99 (2), 639-647. 
34. Chen, A. M.; Santhakumaran, L. M.; Nair, S. K.; Amenta, P. S.; Thomas, T.; He, H. 
X.; Thomas, T. J., Oligodeoxynucleotide nanostructure formation in the presence of 
 103 
  
 
polypropyleneimine dendrimers and their uptake in breast cancer cells. 
Nanotechnology 2006, 17 (21), 5449-5460. 
35. Holzapfel, V.; Musyanovych, A.; Landfester, K.; Lorenz, M. R.; Mailander, V., 
Preparation of fluorescent carboxyl and amino functionalized polystyrene particles by 
miniemulsion polymerization as markers for cells. Macromol. Chem. Physic. 2005, 
206 (24), 2440-2449. 
36. Mislick, K. A.; Baldeschwieler, J. D., Evidence for the role of proteoglycans in 
cation-mediated gene transfer. P. Natl. Acad. Sci. USA 1996, 93 (22), 12349-12354. 
37. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K., Interstitial pH and pO(2) gradients 
in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. 
Nat. Med. 1997, 3 (2), 177-182. 
38. Orwar, O.; Fishman, H. A.; Ziv, N. E.; Scheller, R. H.; Zare, R. N., Use of 2,3-
Naphthalenedicarboxaldehyde Derivatization for Single-Cell Analysis of Glutathione 
by Capillary Electrophoresis and Histochemical-Localization Ion by Fluorescence 
Microscopy. Anal. Chem. 1995, 67 (23), 4261-4268. 
39. Davies, C. D.; Berk, D. A.; Pluen, A.; Jain, R. K., Comparison of IgG diffusion and 
extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro 
as spheroids reveals the role of host stromal cells. Brit. J. Cancer 2002, 86 (10), 1639-
1644. 
40. Pluen, A.; Boucher, Y.; Ramanujan, S.; McKee, T. D.; Gohongi, T.; di Tomaso, E.; 
Brown, E. B.; Izumi, Y.; Campbell, R. B.; Berk, D. A.; Jain, R. K., Role of tumor-host 
 104 
  
 
interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous 
tumors. P. Natl. Acad. Sci. USA 2001, 98 (8), 4628-4633. 
41. Ramanujan, S.; Pluen, A.; McKee, T. D.; Brown, E. B.; Boucher, Y.; Jain, R. K., 
Diffusion and convection in collagen gels: Implications for transport in the tumor 
interstitium. Biophys J. 2002, 83 (3), 1650-1660. 
42. Kleinman, H. K.; Mcgarvey, M. L.; Liotta, L. A.; Robey, P. G.; Tryggvason, K.; 
Martin, G. R., Isolation and Characterization of Type-Iv Procollagen, Laminin, and 
Heparan-Sulfate Proteoglycan from the Ehs Sarcoma. Biochemistry-Us 1982, 21 (24), 
6188-6193. 
43. Boucher, Y.; Baxter, L. T.; Jain, R. K., Interstitial Pressure-Gradients in Tissue-
Isolated and Subcutaneous Tumors - Implications for Therapy. Cancer Res. 1990, 50 
(15), 4478-4484. 
44. Jain, R. K., Transport of Molecules in the Tumor Interstitium - a Review. Cancer Res. 
1987, 47 (12), 3039-3051. 
45. Young, J. S.; Lumsden, C. E.; Stalker, A. L., The Significance of the Tissue Pressure 
of Normal Testicular and of Neoplastic (Brown-Pearce Carcinoma) Tissue in the 
Rabbit. J. Pathol. Bacteriol. 1950, 62 (3), 313-333. 
46. You, C. C.; De, M.; Rotello, V. M., Contrasting effects of exterior and interior 
hydrophobic moieties in the complexation of amino acid functionalized gold clusters 
with alpha-chymotrypsin. Org. Lett. 2005, 7 (25), 5685-5688. 
 
 105 
 
CHAPTER 4 
 
 
 
 
RECOGNITION-MEDIATED ACTIVATION OF THERAPEUTIC GOLD 
NANOPARTICLES INSIDE LIVING CELLS 
 
 
4.1 Introduction 
  Supramolecular chemistry provides a versatile tool for the organization of 
molecular systems into functional structures and the actuation of these assemblies for a 
myriad of applications through the reversible association between complementary 
components. Supramolecular chemistry uses non-covalent interactions to provide 
controlled assembly of molecular building blocks. 1, 2, 3, 4, 5, 6 By virtue of reversible non-
covalent interactions (e.g. hydrogen bonding, ion-ion, pi-pi stacking and van der Waals 
interactions), supramolecular complexes are inherently dynamic in nature and highly 
selective toward other complementary guest molecules through these various weak and 
reversible interactions. 7  As a result of the modularity and the reversibility, 
supramolecular systems can be engineered to assemble and disassemble spontaneously in 
response to a range of triggers. 8 
The versatility of supramolecular chemistry makes this strategy a promising tool 
for biomedical science. A number of host-guest supramolecular systems (e.g. nanovalves 
and artificial molecular machines) have been reported for the delivery of drugs and other 
therapeutic materials. 9 , 10 , 11  The engineering of such systems has been achieved 
principally through the design of molecular recognition partners, thereby fine tuning the 
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molecular recognition event to meet the demands of specific applications. A number of 
synthetic receptors including cucurbit[n]uril (CB[n]),12  cyclodextrins,13, 14 cyclophanes,15 
calixarenes,16  and crown ethers17 , 18  have been used for this purpose. Of these host 
systems, the cucurbit[n]uril (CB[n]) family of macrocyclic receptors is particularly useful 
due to their well defined structure and recognition properties coupled with their ability to 
form stable host-guest inclusion complexes with a wide variety of guest molecules in 
aqueous media.19, 20, 21 This capability has been exploited for the creation of delivery 
vectors, including the encapsulation of platinum drugs inside the cavity of CB[7] to 
increase the stability of the drugs in biological environments. 22 , 23 , 24 , 25   In another 
example, the strong affinity of spermine towards CB[n] has been utilized to tailor a DNA 
delivery vector for enhanced transfection efficiency and target specificity.26, 27  In these 
systems, the properties of the guest molecule have been modified as a result of the 
supramolecular complexation with the host molecules, enhancing delivery properties. 
In addition to modification of molecular properties, supramolecular chemistry 
provides the capability of actuation.28, 29  Engineering of host-guest systems to function 
inside the cell provides a potentially powerful strategy for the regulation of therapeutics. 
We present here a supramolecular system featuring complementary diaminohexane-
terminated gold nanoparticles (AuNP-NH2) and cucurbit[7]uril (CB[7]) that form a non-
toxic assembly that is readily taken up by the cells (Figure 4.1). This host-guest complex 
can be disassembled intracellularly by the orthogonal guest molecule 1-adamantylamine 
(ADA) that features a very high affinity to CB[7]. Intracellular removal of CB[7] from 
the nanoparticle surface results in a endosomal escape by the AuNP-NH2, thereby 
activating the cytotoxicity of AuNP-NH2 and hence inducing cell death (Figure 4.1). This 
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result presents a new strategy for triggering therapeutic systems through the use of 
competitive interactions of orthogonally presented guest molecules, with immediate 
advantages in dosage control and potential utility for dual-targeting therapies. This work 
has been published as an article in the Nature Chemistry journal. 30 
 
 
 
Figure 4.1 Structure of gold nanoparticle and use of intracellular host-guest 
complexation to trigger nanoparticle cytotoxicity. (a) Structure of diaminohexane-
terminated gold nanoparticle (AuNP-NH2) and cucurbit[7]uril (CB[7]). (b) Activation of 
AuNP-NH2-CB[7] cytotoxicity by dethreading of CB[7] from the nanoparticle surface by 
ADA. 
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4.2 Results and discussion  
4.2.1 Complexation/decomplexation between AuNP-NH2 and CB[7] 
The therapeutic component of the system is provided by AuNP-NH2 (2.5 ± 0.4 
nm core size) featuring a self-assembled monolayer of diaminohexane terminated thiol 
ligands (Figure 4.1a).31 The terminal diaminohexane moiety both renders the particle 
cytotoxic (vide infra) and serves as a recognition unit for the formation of host-guest 
inclusion complex with CB[7]. The association constant of this diamine-CB[7] 
complexation process is ~ 108 M-1 and the complex has been shown to be stable under 
biological conditions. 32  The complexation between AuNP-NH2 and CB[7] was 
investigated using NMR titration experiments as shown in Figure 4.2. As the ratio of 
CB[7]/ AuNP-NH2 increases, the peaks for the methylene groups of AuNP-NH2-CB[7] 
are shifted upfield relative to those of AuNP-NH2. This behavior indicates that terminal 
diaminohexane units were encapsulated inside the shielding zone of CB[7] cavity as 
AuNP-NH2-CB[7] complex forms.33 At the ratio of 1:40 (AuNP-NH2:CB[7]), the signal 
shift of the methylene groups was completely saturated, revealing the number of CB[7] 
around a single nanoparticle is ~40. According to the thermogravimetric analysis (TGA), 
the number of diaminohexane-terminated ligands on a single nanoparticle estimated is 
~43 (Figure 4.2b), indicating almost complete encapsulation of diaminohexane units by 
CB[7].  
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Figure 4.2 (a) NMR titration between AuNP-NH2 and CB[7]. The resonance signals for 
the methylene groups and) of AuNP-NH2-CB[7] were shifted upfield, relatively to 
those in AuNP-NH2. (b) Thermogravimetric analysis (TGA) data of AuNP-NH2. The 
average number of diaminohexane-terminated thiol ligand in a single nanoparticle 
estimated is ~43. 
 
 
 
 
 
 
 110 
The AuNP-NH2-CB[7] complex was further characterized through transmission 
electron microscopy (TEM) as shown in Figure 4.3. TEM images taken after uranyl 
acetate staining showed that each gold nanoparticle was encapsulated by CB[7]. The 
average overall diameter of the nanoparticles calculated from the TEM image of AuNP-
NH2-CB[7] is 11.4 ± 0.8 nm, which is in good agreement with the hydrodynamic 
diameter observed by DLS experiment (12.1 ± 0.8 nm). In addition, no size change or 
aggregation of nanoparticles was observed from UV-Vis spectra of the nanoparticles, 
indicating no morphological change after complexation (Figure 4.4). 
 
 
Figure 4.3 TEM image of AuNP-NH2-CB[7] complex after uranyl acetate staining.  
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Figure 4.4 (a) UV-Vis spectra of nanoparticles. 0.6 µM nanoparticles were used to 
measure the absorption spectra. No change in UV-Vis absorption band was observed 
during complexation/decomplexaion process. TEM images of (b) AuNP-NH2, (c) AuNP-
NH2-CB[7], and (d) AuNP-NH2-CB[7] + ADA. No size change or aggregation of 
nanoparticles was observed from TEM images, indicating no morphological change 
during complexation/decomplexation process. TEM samples of AuNP-NH2, AuNP-NH2-
CB[7], and AuNP-NH2-CB[7] unsheathed by ADA were prepared by placing one drop of 
the desired solution (3 μM) on to a 300-mesh Cu grid coated with carbon film. These 
samples were analyzed and photographed using the same instrument without staining. 
The average diameter of Au core is 2.5 ± 0.4 nm. 
 
 
The competitive unsheathing of the AuNP-NH2-CB[7] complex by ADA 
(commonly used as an antiviral or anti-Parkinsonian drug 34, 35, 36) was confirmed using 
NMR and matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS). 
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Addition of ADA triggered the release of CB[7] from nanoparticles through creation of 
the more favorable 1:1 ADA-CB[7] complexes (Ka = 1.7 x 1012). As expected, the shifted 
resonance signals of the methylene groups of the ligands induced by complexation with 
CB[7] were fully recovered as soon as ADA was added (Figure 4.5a). In MALDI-MS, 
the AuNP-NH2 and AuNP-NH2-CB[7] exhibit characteristic ion peaks at m/z 479.44 and 
1641.8 respectively, corresponding to the molecular ion (M+) of [HS-NH2] and [HS-NH2-
CB[7]]. After addition of ADA, the ion peak of [HS-NH2-CB[7]] disappeared and a new 
peak of [ADA-CB[7]] appeared, indicating efficient complexation/decomplxation process 
(Figure 4.5b). 
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Figure 4.5 (a) Competitive behavior of host-guest binding equilibrium on nanoparticle 
was demonstrated by NMR data. The shifted resonance signals of the methylene groups 
of the surface ligands induced by complexation with CB[7] were fully recovered as soon 
as ADA was added to the complex (AuNP-NH2-CB[7]) solution. (b) Matrix-assisted laser 
desorption/ionization mass spectroscopy (MALDI-MS) spectrum. (I) AuNP-NH2, (II) 
AuNP-NH2-CB[7], and (III) AuNP-NH2-CB[7] + ADA 
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4.2.2 Cellular uptake, cytotoxicity and intracellular localization of the nanoparticles  
The cellular uptake of the nanoparticles was quantified using inductively coupled 
plasma mass spectrometry (ICP-MS). ICP-MS analysis revealed that the total amount of 
the nanoparticles taken up by the cells was nearly identical for AuNP-NH2 and AuNP-
NH2-CB[7] (Figure 4.6). TEM analysis of the cells was employed to evaluate the impact 
of CB[7] complexation on the intracellular fate/localization of the nanoparticles. As 
shown in Figure 4.7, after 3 h incubation, both AuNP-NH2 and AuNP-NH2-CB[7] are 
trapped within vesicular structures morphologically consistent with endosomes. This 
observation is consistent with the behavior observed with other cationic nanoparticles, as 
reported in our previous work. 37 , 38  After 24 h of incubation, however, AuNP-NH2 
particles had escaped from the endosome and were dispersed in the cytosol (Figure 4.8). 
In contrast, AuNP-NH2-CB[7] particles remained sequestered in the endosome with no 
free particles observed in the cytosol (Figure 4.8) after the same period. Significantly, 
incubation of AuNP-NH2-CB[7]-treated cells with ADA for 24 h resulted in the escape of 
a substantial number of  particles into the cytosol (Figure 4.8c), consistent with 
intracellular transformation of AuNP-NH2-CB[7] to AuNP-NH2 via dethreading.  
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Figure 4.6 Cellular uptake of the gold nanoparticles. Quantification of the amount of 
gold present in cells. Samples were analyzed by ICP-MS to determine the amount of gold 
in MCF-7 cell after 3 h incubation with 0.5 M of　  AuNP-NH2 and AuNP-NH2-CB[7]. 
Both particles showed almost same cellular uptake. Cellular uptake experiments with 
each gold nanoparticle were repeated 3 times, and each replicate was measured 5 times 
by ICP-MS. Error bars represent the standard deviations of these measurements. 
 
 
 
 
 
 
Figure 4.7 TEM images of cross sectional MCF-7 cells incubated for 3h with 0.5 µM (a) 
AuNP-NH2 and (b) AuNP-NH2-CB[7].  Both particles were similarly trapped in 
organelles such as endosomes. 
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Figure 4.8 Intracellular localization of the gold nanoparticles. TEM images of cross 
sectional MCF-7 cells incubated for 24 h with 2 µM (a) AuNP-NH2 and (b) AuNP-NH2-
CB[7]. Significant amount of AuNP-NH2 is present in the cytosol, however most of the 
AuNP-NH2-CB[7] seems to be trapped in organelles such as endosome. (c) TEM images 
of cross sectional MCF-7 cells incubated for 3 h with 2 µM of AuNP-NH2-CB[7] and 
then further incubation with ADA for 24 h. In the intracellular environment ADA 
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transforms AuNP-NH2-CB[7] to AuNP-NH2, which then escaped from the endosome and 
observed to be dispersed in the cytosol. i, ii and iii are the magnified sections of part (c). 
 
4.2.3 Activating therapeutic efficacy by ADA   
Polyamine functionalized macromolecules 39 , 40 , 41  and nanoparticles 42 , 43 , 44 , 45 
interact strongly with cell membranes and subcellular compartments, resulting in 
membrane disruption and cytotoxicity. Complexation of AuNP-NH2 with CB[7] should 
attenuate the positive charge of the particle surfaces, reducing the ability of the particles 
to disrupt membranes (including the endosomal) and hence lower toxicity. The 
cytotoxicity of AuNP-NH2 and AuNP-NH2-CB[7] was investigated in the human breast 
cancer MCF-7 cell line using an Alamar blue assay. The AuNP-NH2-CB[7] complex was 
substantially less toxic as compared to AuNP-NH2. After 24 h incubation, AuNP-NH2 
exhibited cytotoxicity with an IC50 value of 1.3 µM (Figure 4.9). On the other hand, 
AuNP-NH2-CB[7] complex did not inhibit cell proliferation at concentrations ≤ 50 µM 
under the same experimental conditions, presumably arising from sequestration of the 
particle in the endosome. Significantly, when the free thiol ligand was added to the cells 
at concentrations consistent with those used in the study (80 µM, corresponding to the 
same per-ligand concentration as 2 µM nanoparticle) toxicity was observed with both 
threaded and unthreaded ligand, demonstrating the modulation of ligand toxicity on the 
particle. 
Given the observed intracellular dethreading of AuNP-NH2-CB[7] with ADA and 
concomitant release from the endosome, the endosomal escape of the nanoparticles after 
ADA treatment raises the possibility that toxicity of the AuNP-NH2-CB[7] complex can 
be triggered by ADA. To test this hypothesis MCF-7 cells were incubated with 2 M of 
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AuNP-NH2-CB[7] in culture medium for 3h, to allow endocytosis of nanoparticles.46 
Cells were then washed three times with PBS buffer, and then ADA was added to the 
culture medium. Cells were then incubated for an additional 24 h. Cells treated with 
AuNP-NH2 and AuNP-NH2-CB[7] alone exhibited 34 % and 100 % cell viability after 24 
h incubation, respectively (Figure 4.9b). Treatment with 0.4 mM ADA led to 40 % cell 
viability, approaching the level of lethality observed for the AuNP-NH2 control. The 
result indicates that ADA acts as an effective trigger for the competitive release of CB[7] 
from particles within the cell, with attendant activation of cytotoxicity.  
 
Figure 4.9 Cytotoxicity of AuNP-NH2 and AuNP-NH2-CB[7] and modulating 
cytotoxicity of the gold nanoparticles.  (a) Cytotoxicity of AuNP-NH2 and AuNP-NH2-
CB[7] measured by Alamar blue assay after 24 h incubation in MCF-7. IC50 of AuNP-
NH2 was 1.3　µM and no cytotoxicity of AuNP-NH2-CB[7] was observed up to 50 µM. 
(b) Triggering cytotoxicity using ADA. After 3h incubation of AuNP-NH2-CB[7] (2 µM) 
in MCF-7 cell, different concentrations (0, 0.2 and 0.4 mM) of ADA in medium added 
and further incubated at 37 ºC for 24 h. The cell viability was then determined by using 
an Alamar blue assay. As controls, cell viability of AuNP-NH2 and AuNP-NH2-CB[7] 
was measured after 24 h incubation (34 % and 100 %, respectively). Cell viability 
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experiments were performed as triplicate and the error bars represent the standard 
deviations of these measurements. 
 
4.3 Summary and future outlook   
In summary, we have demonstrated the use of synthetic host-guest chemistry to 
provide triggered activation of a therapeutic system via competitive complexation. This 
approach provides a potential strategy for the construction of synthetic host-guest 
supramolecular systems capable of complex and sophisticated behavior within living 
cells. Triggering therapeutic systems through the use of competitive interactions of 
orthogonally presented guest molecules can be potentially useful for dual-targeting 
therapies, i.e. targeting of both host and guest component. This provides the potential for 
orthogonal (“effector/trigger”) drug delivery and therapeutic activation47, 48 that would be 
capable of achieving higher levels of site specific activity, and reduced amounts of 
collateral damage. Currently, we are exploring this strategy in vivo and thoroughly 
considering issues (e.g. the practical use of ADA) related to the real-world application of 
this system.  
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4.4 Synthesis of materials and experimental methods  
General 
  All the chemicals were purchased from Sigma-Aldrich or Fischer Scientific, unless 
otherwise specified. The chemicals were used as received. Dichloromethane (DCM) used 
as a solvent for chemical synthesis was dried according to standard procedure. The yields 
of the compounds reported here refer to the yields of spectroscopically pure compounds 
after purification. 1H NMR spectra of the nanoparticles and the complexes were recorded 
on a Bruker AVANCE 400 at 400 MHz. MALDI-MS analyses were performed using a 
Bruker Omniflex time-of-flight mass spectrometer. UV-Vis spectra were recorded on 
Hewlett-Packard 8452A spectrophotometer. Dynamic light scattering (DLS) was 
measured by Zetasizer Nano ZS. 
 
4.4.1 Synthesis of ligand and fabrication of nanoparticle  
 
Figure 4.10 Synthetic scheme for the preparation of diaminohexane-terminated ligand.  
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Synthesis of compound 1 
  The trityl-protected thiol ligand (Trt-C11-TEG-OMs) was prepared according to our 
previously reported procedure.49 Trt-C11-TEG-OMs (0.150 g, 0.214 mmol) was first 
dissolved in 2 mL of DCM: MeOH (1:1 v/v) mixture. The solution was then placed in a 
20 mL glass vial and N-Boc-1,6-hexanediamine (0.479 mL, 2.143 mmol) was added to it. 
The reaction mixture was heated to 50°C and stirred for ~48 h. The reaction mixture was 
concentrated under reduced pressure and the residue was directly charged on a SiO2 
column for purification (eluent: a gradient eluent of 0-10% methanol in DCM v/v). Yield 
0.100 g (0.122 mmol, 57%, viscous pale yellow color liquid). 1H NMR (400MHz, 
CDCl3): 7.40 (m, 6H, TrtHAr), 7.27 (m, 6H, TrtHAr), 7.20 (m, 3H, TrtHAr), 4.59 (br, 1H, 
NHCO), 3.88 (t, 3J = 4.64 Hz, 2H, OCH2), 3.68-3.57 (m, 12H, CH2O + 
OCH2), 3.44 (t, 3J = 7.02 Hz, 2H, CH2O), 3.11-3.06 (m, 4H, CH2NCO + 
CCH2N),  2.90 (t, 3J = 8 Hz, 2H, NCH2C), 2.12 (t, 3J = 7.32 Hz, 2H, SCH2), 1.83 
(m, 2H, CH2), 1.59-1.14 (m, 33H, CH2 + C(CH3)3). MS (ESI-MS) calculated for 
C49H76N2O6S 820.5, found 821.8 [M+H]+.   
 
Synthesis of diainohexane-terminated thiol ligand  
  The protected thiol ligand (compound 1, 0.300 g, 0.365 mmol) was dissolved in dry 
DCM. The solution was purged with argon and an excess of trifluoro acetic acid (TFA, 
0.600 mL) was added. During the addition period of TFA the color of the solution was 
turned to yellow.  Subsequently, triisopropylsilane (TIPS, 0.250 mL) was added to the 
reaction mixture and the color of mixture slowly recovered to colorless. The reaction 
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mixture was allowed to stir at room temperature for 6 h under argon atmosphere.  The 
volatile components (solvent, TFA and TIPS) were then distilled off under reduced 
pressure. The pale yellow residue was purified by washing with hexane (15 mL × 3) and 
diethyl ether (15 mL × 3). After drying under high vacuum a viscous colorless liquid was 
obtained. Yield 0.175 g (0.248 mmol, 68%).  1H NMR (400MHz, CDCl3): 3.77 (brt, 3J = 
4.14 Hz, 2H, OCH2), 3.64-3.57 (m, 12H, CH2O + OCH2), 3.44 (t, 3J = 6.94 Hz, 
2H, CH2O), 3.18 (br, 2H, CCH2N),  2.99 (m, 4H, CH2N + NCH2C), 2.51 (q, 4J 
= 7.38 Hz, 2H, SCH2), 1.78-1.26 (m, 26H, CH2). 
   
 
Figure 4.11 Construction of diaminohexane-terminated gold nanoparticle (AuNP-NH2) 
through place exchange reaction. 
 
Procedure for construction of diaminohexane-terminated gold nanoparticle (AuNP-
NH2) 
  Gold nanoparticle (AuNP-NH2) was prepared through place-exchange reaction of 1-
pentanethiol protected gold nanoparticle (Au-C5). Au-C5 was prepared by following the 
procedure reported by Brust et al.50As shown in Figure 5.11, nanoparticle was decorated 
with diaminohexane-terminated thiol ligand by following the general procedure reported 
by Murray et al. In a typical reaction, 0.015 g of Au-C5 was first dissolved in 1 mL of dry 
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DCM. Then, 0.038 g of diaminohexane-terminated thiol ligand dissolved in 5 ml 
DCM:MeOH (4:1 v/v) was added carefully to the solution of Au-C5. The reaction 
mixture was allowed to stir at room temperature for ~ 24 h. After ~ 24 h, argon was 
bubbled through the nanoparticle solution to evaporate the solvents. The dark black color 
nanoparticle residue was then washed with DCM (10 mL × 3) and 5% MeOH in DCM 
v/v (10 mL × 2). After washing the nanoparticle was immediately dissolved in MiliQ 
water and was allowed to stay at room temperature for ~12 h to remove the volatile 
components. The aqueous solution of the nanoparticle was further purified and 
concentrated by using molecular cut off filter (Amicon Ultra-4 tube, 10000 MWCO). The 
filtrate was discarded and the trapped nanoparticle residue (on the cut off filter) was then 
dissolved in D2O.  1H NMR spectra in D2O was then recorded in a 400 MHz Bruker 
machine. The nanoparticle was stable in solution for months and was stored in MiliQ 
water at 4 °C.  
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Figure 4.12 400 MHz 1H NMR spectrum of AuNP-NH2 in D2O. Inset shows the 1H 
NMR spectrum of the diaminohexane-terminated thiol ligand in CDCl3.   
 
4.4.2 Experimental methods  
Cell Culture Experiment  
  MCF-7 cells were grown in a cell culture flask using low glucose Dulbecco's Modified 
Eagle Medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified 
atmosphere of 5% CO2. For cytotoxicity tests involving AuNP-NH2 and AuNP-NH2-
CB[7], MCF-7 cells were seeded at 20,000 cells in 0.2 ml per well in 96-well plates 24 h 
prior to the experiment. During experiment old media was replaced by different 
concentrations of AuNP-NH2 and AuNP-NH2-CB[7] in serum containing media and the 
cells were incubated for 24 h at 37°C in a humidified atmosphere of 5 % CO2. The cells 
were then completely washed with PBS buffer for three times and 10% Alarmar blue in 
serum containing media was added to each well and further incubated at 37 °C for 4 h. 
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The cell viability was then determined by measuring the fluorescence intensity at 570 nm 
using a SpectraMax M5 microplate spectrophotometer. Curves were fitted by DoseRep 
function in Origin 8. For measuring cytotoxicity of AuNP-NH2-CB[7] upon adding ADA, 
MCF-7 cells were seeded at 20,000 cells per well in 96-well plate 24 h prior to the 
experiment. The old medium was replaced by 2 M of AuNP-NH2-CB[7] in medium 
containing serum and incubated for 3h. The cells were then completely washed with PBS 
buffer for three times and different concentration (0, 0.2 and 0.4 mM) of ADA in serum 
containing media was added to the cells and further incubated at 37 ºC for 24 h. The cell 
viability was then determined by using Alamar blue assay.  
 
TEM sample preparation 
   TEM samples of nanoparticles were prepared by placing one drop of the desired 
nanoparticles solution (1~3 µM) on to a 300-mesh Cu grid coated with carbon film, 
followed by 2 % of uranyl acetate staining for 15 min. These samples were analyzed and 
photographed using JEOL 100S electron microscopy.  
  For the preparation of cellular TEM samples, MCF-7 cells were seeded and incubated 
on 15 mm diameter Theramanox® coverslips (Nalge Nunc International, NY) placed in 
24 well plates at amount of 100,000 cells in 1 ml of serum containing media for 24 h 
prior to the experiment. The media was replaced by 0.5 ml of 2 µM AuNP-NH2 or 
AuNP-NH2-CB[7] in serum containing media and incubated for 24 h. The medium 
containing the gold nanoparticles was then discarded and the cells were completely 
washed with PBS buffer for three times. The cells were then fixed in 2 % glutaraldehyde 
with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 30 min and then 
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washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. They were 
postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate buffer 
solution (pH 7.0) for 1 hr and the rinsed with distilled water three times. They were 
dehydrated in a graded series of acetone (10 % step), and embedded in epoxy resin. The 
resin was polymerized at 70 °C for 12 h. Ultrathin sections (50 nm) obtained with a 
Reichert Ultracut E Ultramicrotome and imaged under a JEOL 100S electron 
microscopy.   
  For the preparation of TEM samples for the cells treated with AuNP-NH2-CB[7] and 
subsequent incubation with ADA, pre-seeded MCF-7 cell on 15 mm diameter 
Theramanox® coverslips was treated by AuNP-NH2-CB[7] (2 M) for 3h. After washing 
three times with PBS buffer, the cells were further incubated with ADA (0.4 mM) in 
serum containing media for 24 h. Cellular TEM sample was prepared according to the 
above described procedure. 
 
ICP-MS sample preparation and experimental setup 
  ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating 
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15 
L/min; nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 197Au; dwell time: 50 ms; 
nebulizer: cross flow; spray chamber: Scott. AuNP-NH2 and AuNP-NH2-CB[7] (0.5 M) 
was incubated with pre seeded MCF-7 cell line in 24 well plates (20,000 cells/well) for 
3h. After incubation, cells were washed three times with PBS buffer and then lysis buffer 
(250 l) was added to the cells. The resulting cell lysate was digested overnight using 3 
mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of aqua regia was added, and 
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then the sample was allowed to react for another 2-3 h. The sample solution was then 
diluted to 100 mL with de-ionized water, and aqua regia. The final gold nanoparticle 
sample solution contained 5% aqua regia. The gold nanoparticle sample solution was 
measured by ICP-MS under the operating conditions described above. Cellular uptake 
experiments with each gold nanoparticle were repeated 3 times, and each replicate was 
measured 5 times by ICP-MS. A series of gold standard solutions (20, 10, 5, 2, 1, 0.5, 
0.2, 0 ppb) were prepared before each experiment. Each gold standard solution contained 
5% aqua regia. The resulting calibration line was used to determine the gold amount in 
taken up by the cells in each sample. 
 
Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) 
  The MALDI analyses were done on a Bruker Omniflex time-of-flight mass 
spectrometer. The spectrometers are equipped with a 337 nm nitrogen laser, a 1.0 m 
flight tube, and a stainless steel sample target. All mass spectra were acquired in a 
reflectron mode, using a reflectron voltage of 20 kV. All reported spectra represent an 
average of 100 shots. A saturated matrix (α-cyano-4-hydroxycinnamic acid (α-CHCA)) 
solution was prepared in 70% acetonitrile, 30% H2O, and 0.1% trifluoroacetic acid. 1 μL 
of matrix solution was mixed with 1 μL of nanoparticle solution. 1 μL of this mixture was 
applied to target, and after allowing it to dry, the MALDI-MS analysis was performed. 
 
Thermogravimetric analysis (TGA) 
  TGA was performed using a TGA 2950 high-resolution thermo-gravimetric analyzer 
(TA Instruments, Inc., New Castle, DE), which was equipped with an open platinum pan 
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and an automatically programmed temperature controller. The TGA data were obtained 
as follows: about 3.0 mg of AuNP-NH2 was placed in the TGA pan and heated in a 
nitrogen atmosphere at a rate of 5 °C / min up to 500 °C. The mass change was plotted 
against temperature to generate the thermogravimetric combustion profile of AuNP-NH2. 
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CHAPTER 5 
 
 
 
REGULATING EXOCYTOSIS OF GOLD NANOPARTICLES VIA HOST-
GUEST CHEMISTRY 
 
 
 
 
 
5.1 Introduction 
  Drug delivery systems (DDSs) improve the efficacy of conventional 
pharmaceutics through enhanced pharmacokinetics and biodistribution.1 Drugs can be 
both covalently and non-covalently incorporated into DDSs.2 Successful therapy with 
DDSs achieves accurate delivery of their associated drugs to target cells through 
controlled drug release.3 Release of drugs from carriers can be regulated by employing 
tunable activation strategies (e.g. hydrolysis or degradation) via relevant stimuli (e.g. the 
low endosomal pH, light, and cytosolic reductive conditions). 4 , 5 , 6   Because greater 
antiproliferative activity of the drugs relies on the sustained therapeutic effect inside 
cells, cellular uptake and subsequent long-term retention of the drug carriers within the 
cells are required for efficient DDSs.7, 8, 9 
One of the main obstacles of DDSs, however, is the rapid removal of the 
internalized drug carriers by exocytosis from the cells before the loaded therapeutics are 
effective.10, 11 Exocytosis is the process of expelling wastes and other large molecules out 
of the cells,12 which is also commonly observed with a wide variety of drug carriers.13, 14 
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As an example, internalized poly (D,L-lactide-co-glycolide) nanoparticles undergo 
exocytosis to the extent of 65 % at 30 min and 85 % at 6 h.15 Reducing exocytosis of the 
nanoparticulate drug carriers thus can lead their prolonged retention and sustained release 
of the loaded drugs inside of the cells, enhancing therapeutic efficiency of the DDSs.16, 17 
To date, there have been no reported strategies preventing exocytosis of the nanoparticles. 
Furthermore, developing strategies for an orthogonal control of the exocytosis in the 
cellular environment is a major challenge because of the intracellular chemical 
complexity and a potential toxicity of relevant reagents. To solve the issues, an 
orthogonally non-toxic modular system under biological condition should be addressed.  
Supramolecular chemistry can develop controlled assemblies from molecular 
building blocks by virtue of reversible non-covalent interactions including hydrogen 
bonding and van der Waals interactions.18 Due to their modular properties toward other 
complementary molecules, host-guest supramolecular complexes can be tuned to 
assemble and dissemble in response to various triggers,19 providing a powerful tool for 
creating a number of host-guest systems for therapeutic applications.20, 21, 22 Of the host-
guest systems, the use of cucurbit[n]ril (CB[n]) family is useful due to its ability to form 
stable host-guest complexes with a wide variety of guest molecules in aqueous media,23, 
24 and its non-toxic behavior in vitro and in vivo. 25,  26  Various CB[n]-guest systems have 
been developed to create delivery vectors for the drugs and other therapeutic materials, 
and an actuator system to control catalytic activity of an enzyme. 27 , 28 , 29  Moreover, 
owing to the high binding affinity of CB[n] to guest molecules (up to 1013 M-1), 
engineering of the host-guest systems provides the capability of actuation for the 
regulation of therapeutics in living cells.30, 31 
 137 
In this work, we describe a strategy to regulate exocytosis of AuNPs by utilizing 
the host-guest system on gold nanoparticles (AuNPs).32, 33 Quaternary amine head group 
terminated cationic gold nanoparticles (AuNP-TBen) were readily taken up by the cells 
via endocytosis (Figure 5.1). Afterward, in situ treatment of a complementary 
cucurbit[7]uril (CB[7]) resulted in threading of the CB[7] on AuNP-TBen inside the cells. 
The AuNP-TBen-CB[7] complexation rendered the surface of the particles less 
hydrophilic, inducing the assemblies of AuNP-TBen-CB[7] sequestered in the endosome. 
Exocytosis of the AuNP-TBen-CB[7] was then blocked by the increased size of the 
induced assemblies. This approach provide a new strategy for improving efficacy of drug 
delivery systems through prolonged retention of drug carriers within the cells. 
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Figure 5.1 Controlling exocytosis of the nanoparticle by using intracellular host-guest 
complexation. (a) Inhibition of AuNP-TBen exocytosis by threading of CB[7] on the 
nanoparticle surface. (b) Inducement of the AuNP-TBen-CB[7] assemblies. 
 
 
5.2 Results and discussion 
5.2.1 Complexation between AuNP-TBen and CB[7]  
Exocytosis of nanoparticles is dependent on their size.7 Larger nanoparticles 
(more than 100 nm in diameter) undergo exocytosis at slower rate and lower amount than 
smaller nanoparticles. Therefore, the underlying principle of controlling exocytosis of 
nanoparticles is to induce in situ growth of assemblies from the internalized individual 
nanoparticles entrapped in endocytic vesicles by using a host-guest supramolecular 
system. The exocytosis of the particles then would be blocked by the increased size of the 
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induced assemblies 34  and the host-guest system provides an orthogonal stimulus, 
allowing temporal control of the exocytosis (Figure 5.1 (b)). 
To provide an effective host-guest supramolecular system, we synthesized a 
water-soluble gold nanoparticle, AuNP-TBen, featuring a tetra(ethylene glycol) and 
quaternary benzyl amine head group at terminal ligand via a Murray’s place-exchange 
reaction.35 The detailed syntheses and characterization of the AuNPs are available in the 
Supporting Information. The gold core had an average size of 2.1 ± 0.5 nm with 
hydrodynamic diameter of the AuNP-TBen being 9.7 ± 0.1 nm determined by TEM and 
dynamic light scattering, respectively. The AuNP-TBen had a positive potential of + 14.2 
mV. The terminal quaternary benzyl amine moiety serves as a recognition unit for the 
formation of a host-guest inclusion complex with CB[7] with the association constant of 
~ 10-8 M-1.36 This higher binding constant is strong enough for the complexes to remain 
stable under biological conditions.37 
 
5.2.2 Inducing assemblies of AuNP-TBen-CB[7]  
The complexation between AuNP-TBen and CB[7] was investigated by using 
DLS experiments as shown in Figure 5.2(a). At the molar ratio of 1:1 and 1:2 (AuNP-
TBen:CB[7]), the hydrodynamic diameter of the AuNP-TBen slightly increased from 9.7 
± 0.1 to 11.6 ± 0.5 nm. At a ratio of 1:4 (AuNP-TBen:CB[7]), the particles began to 
assemble to each other and were completely assembled (aggregated) precipitating at the 
ratio of 1:10 (AuNP-TBen:CB[7]) as shown in Figure 5.1 (b). The controls, AuNP-
TTMA and AuNP-TCOOH showed no observable change of diameter upon adding CB[7] 
as both particles have no interaction with CB[7]. 
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Figure 5.2 Inducing assemblies of the nanoparticle upon binding with CB[7] and effect 
of surface functional group of the particle. (a) DLS experiments of the nanoparticles 
depending on addition of CB[7]. It is noted that AuNP-TBens were completely 
assembled (aggregated) and precipitated at the ratio of 1:10 (AuNP-TBen:CB[7]). (b) 
AuNP-ADA and AuNP-TMC6 induce the assemblies upon binding with CB[7] (at the 
ratio of 1:10 (AuNPs:CB[7]), but not for AuNP-TMOH and AuNP-TMNH2 with polar 
end groups. Inducement of the assemblies of the particles is dependent on surface 
functional group of the particles 
 
To explain the rationale of the induced assemblies of the AuNP-TBen-CB[7], 
inducement of the assemblies upon binding with CB[7] was carried out with 
nanoparticles having different surface functional groups (Figure 5.2 (b)). AuNP-ADA 
and AuNP-TMC6 induced the assemblies (aggregates) upon binding with CB[7] (at the 
ratio of 1:10 (AuNPs:CB[7]) as AuNP-TBen-CB[7] complex. In contrast, AuNP-TMOH 
and AuNP-TMNH2 could not induce assemblies although the particles-CB[7] complexes 
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were formed. This indicates that the surface end group of the particles plays important 
role in inducing the assemblies of the particles. 
The amphiphilic nanoparticle, AuNP-TBen (also AuNP-ADA and AuNP-TMC6) 
are soluble in both aqueous and organic solvent (e.g. dichloromethane), respectively. In 
the aqueous solution, the hydrophobic benzyl units on the particles are probably hidden 
from the external environment, making the surface of the particles hydrophilic and 
soluble in aqueous media. Upon binding with CB[7], the benzyl units on the particle 
presumably became stretched out along the particle, rendering the surface of the particle 
forcefully less hydrophilic, decreasing their solubility, and inducing the assemblies 
(Figure 5.1 (b)). AuNP-TMOH and AuNP-TMNH2 can bind with CB[7] but hydroxyl 
and amine end group potentially kept the surface of particles hydrophilic, and therefore 
not allowing assemble of the particles. It indicates that inducing assemblies is dependent 
on surface functional group of the particles.   
When the particle assemblies of AuNP-TBen-CB[7] were treated with excess of 
1-adamantyl amine (ADA), CB[7] is dethreaded from the particle through creation of the 
more favorable 1:1 ADA-CB[7] complexes (Ka = 1.7 x 1012).24 Addition of ADA 
triggered the particle assemblies to disassemble, making the particles soluble back into 
the PBS (Figure 5.3). This indicates that exploiting host-guest systems on AuNPs can 
control solubility (hydrophobicity) of the AuNPs by using precise ‘lock and key’ 
modulation over their molecular-level interactions. 
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Figure 5.3 (a) AuNP-TBen in PBS. (b) AuNP-TBen-CB[7] assemblies (c) When the 
particle assemblies of AuNP-TBen-CB[7] were treated with excess of 1-adamantyl amine 
(ADA), ADA triggered the particle assemblies to disassemble, making the particles 
soluble back in PBS.  
 
5.2.3 Controlling exoctosis of AuNP-TBen-CB[7]  
Cellular uptake behaviors of the nanoparticles were investigated by TEM analysis 
of the cell. After 3h incubation of the cationic AuNP-TBen (200 nM), the particles were 
shown to be trapped in the endosomal vesicles in cytoplasm as shown in Figure 5.4 (a). 
This observation is consistent with a endocytotic behavior of other cationic nanoparticles 
previously reported in literatures. 38 , 39  To study the exocytotic behaviors of the 
nanoparticle, after 3h incubation of the AuNP-TBen (200 nM), the cells were washed off 
and incubated with fresh media or CB[7] (0.2 mM) media for an additional 24h. When 
the cells were treated by fresh media, the number of the particle-entrapped vesicles was 
significantly decreased (Figure 5.4 (b)). Only a few particles remained within the vesicles 
or dispersed in various organelles, indicating a major portion of the removed AuNP-TBen 
NH2CB[7]
(a) (b) (c)
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from the cells were involved in exocytosis. In contrast, when the cells were treated by the 
CB[7] media (0.2 mM) to induce assemblies of AuNP-TBen-CB[7], the particles 
remained trapped in the endosome (Figure 5.4 (c)). These results indicate that treatment 
of CB[7] caused intracellular assemblies of the AuNP-TBen-CB[7] as the CB[7] can 
cross the cell membrane40 and the induced bulky assemblies remained sequestered in 
endocytic vesicles without exocytosis.  
 
  
 
Figure 5.4 Cellular uptake and intracellular behavior of the gold nanoparticles. (a) TEM 
images of cross sectional MCF-7 cells incubated for 3 h with 200 nM of AuNP-TBen. 
The cationic AuNP-TBen seems to be trapped in organelles such as an endosome (in the 
red circle). (b) TEM images of cross sectional MCF-7 cells incubated for 3 h with 200 
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nM of AuNP-TBen and then washed off and further incubation with only cell culture 
media for 24 h. The number of the particle-entrapped endosomal vesicles was 
significantly decreased. (c) TEM images of cross sectional MCF-7 cells incubated for 3 h 
with 200 nM of AuNP-TBen and then washed off and further incubation with cell culture 
media of CB[7] (0.2 mM) for 24 h. (d) Quantification of the amount of gold retained in 
cells at different time (0 h, 3 h, 12 h, and 24 h). Samples at each time point were analyzed 
by ICP-MS to determine the amount of gold in MCF-7 cell after 3 h incubation with 200 
nM of AuNP-TBen and washed off and further incubation with media or media of CB[7] 
(0.2 mM). Cellular uptake experiments with each gold nanoparticle were repeated 3 
times, and each replicate was measured 5 times by ICP-MS. Error bars represent the 
standard deviations of these measurements. 
 
The excocytosis of the nanoparticles was further quantified by using inductively 
coupled plasma mass spectrometry (ICP-MS). After 3h incubation of AuNP-TBen (200 
nM), the cells were completely washed off and replaced by fresh cell culture media or 
CB[7] (0.2 mM) media. The cells were then incubated for different additional times (0 h, 
3 h, 12 h, and 24 h) and the amount of the gold nanoparticle retained by the cells was 
determined by measuring ICP-MS.  Retention of the AuNP-TBen treated by only cell 
culture media decreased 34 % at 24 hours while no significant change was observed for 
the media of CB[7] treatment (Figure 5.4 (d)). This result revealed that treatment of the 
CB[7] on the cells inhibited exocytosis of the AuNP-TBen along with the observed TEM 
results. 
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5.2.4 Effect of an end group on the exocytosis  
To further investigate the effect of an end group of AuNPs on the exocytosis, 
retention of the particles with different functional head groups in the cells was measured 
by using ICP-MS. AuNP-TTMA and AuNP-TMOH (Figure 5.4 (a) and (b)) exhibited no 
significant difference of exocytotic behavior for both media and media of CB[7] 
treatments, showing no effect of CB[7] on exocytosis of the AuNPs. Retention of the 
AuNP-TTMA and AuNP-TMOH decreased to ~ 62 % and ~ 70 % at 24h, respectively, 
regardless of CB[7] treatment. In the other hand, exocytosis of the AuNP-ADA and 
AuNP-TMC6 was blocked when the cells were treated by media of CB[7] as the AuNP-
TBen (Figure 5.5 (c) and (d)). Amount of the retained AuNP-ADA and AuNP-TMC6 in 
the cells reduced to ~ 75 % and ~ 70 % at 24h for the media treatment.  Both AuNP-ADA 
and AuNP-TMC6 induced assemblies of the particle upon binding with CB[7] as AuNP-
TBen. It indicates that CB[7] itself does not affect cellular uptake of the particles and 
exocytosis of the particles was caused increased size of the assemblies. 
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Figure 5.5 Effect of a surface functional group on exocytotic behavior of AuNPs. ICM-
MS measurements of  (a) AuNP-TTMA, (b) AuNP-TMOH, (c) AuNP-TMC6, and (d) 
AuNP-ADA. Quantification of exocytosis of the particles were determined by analyzing 
ICP-MS on MCF-7 cell with same experimental condition carried out on the AuNP-TBen. 
AuNP-TTMA does not bind with CB[7]. AuNP-TMOH binds with CB[7] but does not 
induce assemblies. Both AuNP-ADA and AuNP-TMC6 induced assemblies of the 
particle upon binding with CB[7]. Cellular uptake experiments with each gold 
nanoparticle were repeated 3 times, and each replicate was measured 5 times by ICP-MS. 
Error bars represent the standard deviations of these measurements. 
 
5.2.5 Cellular viability  
Cellular proliferative activity was measured by alamar blue assay to evaluate 
possible toxicity that might arise from nanoparticles while retained in the cells. As shown 
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in Figure 5.6, all the nanoparticles exhibited no decrease in cell viability for the treatment 
of both media and media of CB[7] (0.2 mM). It shows that the induced assemblies of the 
particles sequestered in endocytic vesicles do not affect cell viability. 
 
Figure 5.6 Cytotxicity of gold nanoparticles. After 3h incubation of AuNPs (200 nM) in 
MCF-7 cell, the cells were washed off and further incubated with media and media of 
CB[7] (0.2 mM) at 37 ºC for 24 h. The cell viability was then determined by using 
Alamar blue assay. As a control, CB[7], cell viability of CB[7] (0.2 mM) was measured 
after 24 h incubation.  
 
 
5.3 Summary and future outlook  
In conclusion, we have demonstrated a methodology for regulating exocytosis of 
the internalized nanoparticles. Utilizing supramolecular host-guest system on the AuNPs 
induced the assemblies of the particles in the living cells, preventing their exocytosis 
without any observed cytotoxicity. This approach would provide a potential strategy for 
prolonged retention of drug carriers within endosome, enabling sustained therapeutic 
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effect of the carriers. We are currently exploring this strategy with AuNPs featuring 
prodrugs tethered with labile linkage which can be degraded by external stimuli. 
Additionally, this approach also will be applied to other nanomaterials with potential 
utility of their prolonged transplantation in a wide variety of cells for in vivo cellular 
tracking41 and tumor-targeted delivery of therapeutic systems.42 
 
  
5.4 Synthesis of materials and experimental methods  
General 
 All the chemicals were purchased from Sigma-Aldrich or Fischer Scientific, unless 
otherwise specified. The chemicals were used as received. Gold nanoaprticles used in this 
work have been reported previously. 43  1H NMR spectra were recorded at 400 MHz on a 
Bruker AVANCE 400 machine. Hewlett-Packard 8452A UV-Vis spectrophotometer was 
used to record UV-Vis spectra. Dynamic light scattering (DLS) was measured by 
Zetasizer Nano ZS. The fluorescence from the Alamar blue assay was measured in a 
SpectraMax M5 microplate spectrophotometer. 
 
ICP-MS sample preparation and measurements 
  ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating 
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15 
L/min; nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 197Au; dwell time: 50 ms; 
nebulizer: cross flow; spray chamber: Scott. Gold nanoparticles (200 nM, 0.5 ml) was 
incubated with pre-seeded MCF-7 cell line in 24 well plates (20,000 cells/well) for 3h. 
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After incubation, cells were washed three times with PBS buffer and then 0.5 mL of 
media or media of CB[7] (0.2 mM) was added to the cells. The wells of the plates then 
connected to a peristaltic pump which provides a continuous flow of the media and media 
of CB[7] to remove exocytosed nanoparticles. The cells were then incubated for different 
additional times (0 h, 3 h, 12 h, and 24 h). Cells were washed three times with PBS buffer 
and then lysis buffer (300 l) was added to the cells. The resulting cell lysate was 
digested overnight using 3 mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of 
aqua regia was added, and then the sample was allowed to react for another 2-3 h. The 
sample solution was then diluted to 100 mL with de-ionized water, and aqua regia. The 
final gold nanoparticle sample solution contained 5% aqua regia. The gold nanoparticle 
sample solution was measured by ICP-MS under the operating conditions described 
above. Cellular uptake experiments with each gold nanoparticle were repeated 3 times, 
and each replicate was measured 5 times by ICP-MS. A series of gold standard solutions 
(20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb) were prepared before each experiment. Each gold 
standard solution contained 5% aqua regia. The resulting calibration line was used to 
determine the gold amount in taken up by the cells in each sample. 
 
Cellular TEM measurements 
  For a preparation of cellular TEM samples, MCF-7 cells were seeded and incubated on 
15 mm diameter Theramanox® coverslips (Nalge Nunc International, NY) placed in 24 
well plates at amount of 100,000 cells in 1 ml of serum containing media for 24 h prior to 
the experiment. The media was replaced by 0.5 ml of 200 nM AuNP-TBen in serum 
containing media and incubated for 3 h. The cells were completely washed with PBS 
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buffer for three times and then 0.5 mL of media or media of CB[7] (0.2 mM) was added 
to the cells. After another 24 h incubation, the cells were then fixed in 2 % glutaraldehyde 
with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 30 min and then 
washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. They were 
postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate buffer 
solution (pH 7.0) for 1 hr and the rinsed with distilled water three times. They were 
dehydrated in a graded series of acetone (10 % step), and embedded in epoxy resin. The 
resin was polymerized at 70 °C for 12 h. Ultrathin sections (50 nm) obtained with a 
Reichert Ultracut E Ultramicrotome and imaged under a JEOL 100S electron 
microscopy.   
 
Cell culture and cytoxicity TEM measurements 
  MCF-7 cells were grown in a cell culture flask using low glucose Dulbecco's Modified 
Eagle Medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified 
atmosphere of 5% CO2. For a cytotoxicity test, MCF-7 cells were seeded at 20,000 cells 
in 0.2 ml per well in 96-well plates 24 h prior to the experiment. During experiment old 
media was replaced by 0.2 ml of nanoparticles (200 nM) in serum containing media and 
the cells were incubated for 3 h at 37°C in a humidified atmosphere of 5 % CO2. The 
cells were then completely washed with PBS buffer for three times and media or media 
of CB[7] (0.2 mM) was added to the cell. After another 24h incubation, the cells were 
then completely washed off and 10% Alarmar blue in serum containing media was added 
to each well and further incubated at 37 °C for 4 h. The cell viability was then determined 
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by measuring the fluorescence intensity at 570 nm using a SpectraMax M5 microplate 
spectrophotometer. 
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